In vivo pool-based shRNA screens to identify modulators of disease progression in hematopoietic malignancies by Meacham, Corbin Elizabeth
	    	  
In vivo pool-based shRNA screens to identify modulators of 
disease progression in hematopoietic malignancies 
by 
Corbin Elizabeth Meacham 
 
B.S. Biology 
University of Chicago, 2006 
 
Submitted to the Department of Biology in partial fulfillment of the requirements 
for the degree of  
Doctor of Philosophy in Biology 
at the 
Massachusetts Institute of Technology 
 
February 2012 
 
© 2012 Massachusetts Institute of Technology. All rights reserved. 
 
Signature of Author: ________________________________________________ 
               Department of Biology 
                   December 21, 2011 
 
Certified by: ______________________________________________________ 
                    Michael T. Hemann 
            Associate Professor of Biology 
                      Thesis Supervisor 
 
Accepted by: _____________________________________________________ 
                Tania A. Baker 
           E. C. Whitehead Professor of Biology 
           Co-chairman, Biology Graduate Committee 
	  	   2	  
In vivo pool-based shRNA screens to identify modulators of disease 
progression in hematopoietic malignancies 
 
by 
Corbin Elizabeth Meacham 
 
Submitted to the Department of Biology on January 12, 2012 in Partial Fulfillment of the 
Requirements for the Degree of Doctor of Philosophy in Biology 
 
Abstract 
 
 shRNA screens have been very effective in identifying novel cancer genes in 
mammalian cells, but they have primarily been limited to in vitro applications in tumor cell 
lines. Whereas in vivo retroviral mutagenesis screens typically identify gain-of-function 
alterations in positive selection screens, shRNA screening approaches allow for the 
systematic interrogation of the impact of loss of function events across large gene sets. 
Using transplantable mouse models of Eµ-myc lymphoma and Bcr-Abl driven B-cell 
acute lymphoblastic leukemia, we have adapted shRNA screening approaches to in vivo 
applications and have performed large-scale loss of function genetic screens in tumors.  
 Initial work suggested that screens with complex shRNA libraries could be 
performed in the in vivo setting using a model of Eµ-myc lymphoma. Here, the 
introduction of an shRNA library into lymphoma cells ex vivo, followed by transplantation, 
showed that as many as 1000 unique hairpins were represented in tumors in individual 
recipient animals. The set of genes targeted by shRNAs that negatively impacted 
lymphoma cell growth in vivo was highly enriched for regulators of cell motility, and 
suppression of these genes, which included Rac2, CrkL, and the poorly characterized 
actin monomer binding protein Twf, impaired lymphoma progression and tumor cell 
dissemination to sites of terminal metastatic disease. Additionally, suppression of Rac2 
and Twf improved chemotherapeutic outcome, suggesting that lymphoma cell migration 
following therapy, from sites of minimal residual disease to sites of terminal disease, 
may be an important event in relapse. 
 In a second screen using a BCR-Abl B-cell acute lymphoblastic leukemia model, 
we found that as many as 9,000 unique shRNAs could be identified in individual animals 
following tumor cell transplantation. Based on this result, we were able to perform an 
unbiased screen for modulators of leukemia cell growth in vivo using a genome-scale 
shRNA library composed of five pools of 10,000 shRNAs each. shRNAs that negatively 
impacted leukemia cell growth specifically in vivo were selected for validation, which 
included a set of hairpins targeting poorly characterized C2H2 zinc finger proteins. While 
neutral in the in vitro setting, a number of these shRNAs validated as single constructs in 
vivo. As an additional filter to select candidates for validation, we compared the set of 
genes targeted by candidate hairpins with genes that are transcriptionally upregulated in 
leukemia cells in vivo, and the leukemia genes Runx and Lmo2 met both of these 
criteria. Suppression of Runx and Lmo2 was selected against in tumors, suggesting that 
oncogenic pathways downstream of these genes may be used for leukemia cell growth 
or survival in vivo. We also compared the set of genes targeted by depleting hairpins 
with published DNA copy number alteration data from human ALL patients. In validation 
studies, we identified genes within regions of genomic alteration that impacted tumor cell 
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proliferation in vivo. One of these genes was the plant homeodomain finger protein Phf6. 
While inactivating mutations in Phf6 are a common alteration in T cell malignancies, we 
found that suppression of this gene negatively impacted the growth of B cell 
malignancies in vivo, indicative of lineage-specific role for Phf6 in hematopoietic tumors.  
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Insertional mutagenesis screening in hematopoietic malignancies 
 
 Historically, genetic screens have been performed using the slow transforming 
viruses MuLV (murine leukemia virus) and MMTV (mouse mammary tumor virus) in the 
mouse hematopoietic system and mammary glands, respectively. Unlike acute 
transforming viruses, which contain viral oncogenes that rapidly induce disease in 
inoculated animals following infection, these viruses produce malignancies with a 
protracted latency, and their effect is mediated by viral alterations of host cell gene 
expression rather than by viral expression of an oncogene (Hayward et al., 1981; 
Jenkins et al., 1981; Neel et al., 1981; Varmus et al., 1981). In the case of MLV-induced 
disease, newborn mice are infected with the virus, which then propagates in the 
hematopoietic compartment (Rowe and Pincus, 1972). The virus stably integrates into 
the genome of host cells, and depending on the integration event, can either disrupt 
gene function, or enhance gene expression, with viral promoter or enhancer elements 
driving expression of proximal genes. When the integration event provides a selective 
advantage, or promotes transformation of the host cell, clonal outgrowth will occur, 
yielding hematopoietic tumors. Frequently, multiple clonal populations contribute to 
tumors in individual mice. Candidate transforming genes can then be identified based on 
their proximity to common insertion sites, or sites of viral integration in the genome that 
are found in multiple independent tumors at a frequency that is higher than expected by 
chance (Jonkers and Berns, 1996; Kool and Berns, 2009; Uren et al., 2005). 
Additionally, individual cells can undergo multiple rounds of infection, suggesting that 
sequential integration events near oncogenes at different stages of transformation may 
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contribute to disease development and progression (Cuypers et al., 1986; Kool and 
Berns, 2009; Selten et al., 1984). 
 Insertional mutagenesis screens have effectively identified a number of key 
oncogenes in hematopoietic malignancies. Typically, Moloney MuLV infection of 
newborn mice produces T cell lymphomas; in these tumors, Myc (Corcoran et al., 1984; 
Selten et al., 1984) and Pim-1 (Cuypers et al., 1984; Selten et al., 1985) are frequently 
proximal to common insertion sites, resulting in upregulation of expression of these 
genes. In the case of Myc, this upregulation has been attributed to viral enhancer 
elements, whereas in the case of Pim-1, integration of the virus into the 3’ region of the 
gene is thought to truncate the 3’ UTR, stabilizing the transcript. Viruses can also induce 
gene expression by integrating into promoter regions. In a mouse strain predisposed to 
develop myeloid tumors (Mucenski et al., 1986), a common retroviral insertion site was 
identified in the promoter of Evi-1 (Mucenski et al., 1988). While Evi-1 is not normally 
expressed at high levels in hematopoietic tissues, viral activation of this zinc finger 
protein seems to negatively impact the ability to myeloid cell lines to terminally 
differentiate (Morishita et al., 1988). 
 Alternatively, viral integrations can truncate cellular transcripts, resulting in the 
deletion of regulatory protein domains and producing gene products that are highly 
oncogenic. This type of viral alteration has been observed in Notch in T cell lymphomas, 
in which truncating viral insertions produce a gene product that lacks the 5’ ligand-
binding extracellular domain, rendering Notch ligand independent. Additional insertions 
have also been observed in the carboxyl terminus of Notch, which results in increased 
stability of the Notch protein (Feldman et al., 2000; Girard et al., 1996; Hoemann et al., 
2000). Interestingly, both of these alterations mimic mutations that are observed in a 
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large proportion of human T-cell acute lymphoblastic leukemia patients (Weng et al., 
2004). 
 In addition to identifying genes that promote tumor development, insertional 
mutagenesis screens have also been used to identify genes that cooperate with other 
oncogenes in accelerating tumor development. In these instances, insertional 
mutagenesis screens have been performed in transgenic mice that are predisposed to 
develop specific hematopoietic malignancies. Infection of these animals with a 
mutagenic virus reduces the latency to disease development, and cooperating 
oncogenes are found proximal to common insertion sites. In early studies with mice 
expressing high levels of the putative oncogene Pim-1, in which only a small percentage 
of animals develop T cell lymphomas, infection with MuLV accelerated disease onset, 
and 100% of animals developed malignancies. In the resulting tumors, either c-Myc or n-
Myc were activated by viral insertions, suggesting that Myc and Pim-1 cooperate in the 
development of T cell malignancies (van Lohuizen et al., 1989).  
 In reciprocal insertional mutagenesis screens, Pim-1 was identified as a 
cooperating oncogene in Eµ-myc transgenic mice. In these mice, expression of high 
levels of Myc in the B cell compartment predisposes animals to develop B cell 
lymphomas (Adams et al., 1985), and infection of these animals with MuLV results in 
accelerated B cell, rather than T cell, malignancies, demonstrating that the Eu-myc 
transgenic background can alter the tumor spectrum of MuLV-induced tumors. 
Additionally, this data indicates that these Myc and Pim-1 can cooperate in the 
development of both B and T cell malignancies (Haupt et al., 1991; van Lohuizen et al., 
1991). The oncogenic cooperation between Myc and Pim-1 was functionally validated in 
crosses between Eµ-Myc and Eµ-Pim-1 mice, where Pim-1 accelerates 
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lymphomagenesis in Eµ-Myc animals; Eµ-Myc Eµ-Pim-1 animals develop a prenatal B-
cell lymphoblastic leukemia, whereas Eµ-Myc animals develop B cell malignancies with 
a latency of 2.5 to 12 months (Verbeek et al., 1991).  
 In addition to identifying Pim-1, insertional mutagenesis screens have also 
identified a novel zinc finger protein and putative transcriptional regulator, Bmi-1, as 
cooperating with Myc in lymphoma development. Validation studies have shown that 
Bmi-1 can function as an oncogene; mice overexpressing Bmi-1 develop B and T cell 
malignancies, and elevated Bmi-1 expression accelerates Myc-mediated 
lymphomagenesis (Alkema et al., 1997; Haupt et al., 1993). Bmi-1 has since been 
shown to be a polycomb group protein that negatively regulates the Ink4a-Arf locus and 
thus cooperates with Myc by preventing Myc-mediated upregulation of this locus and the 
induction of apoptosis (Jacobs et al., 1999a; Jacobs et al., 1999b). 
 More recent advances in sequencing technology, as well as annotation and 
assembly of the mouse genome, have facilitated the discovery of large numbers of novel 
common insertion sites and candidate oncogenes in insertional mutagenesis screens (Li 
et al., 1999; Lund et al., 2002; Mikkers et al., 2002; Suzuki et al., 2002). By PCR 
amplifying and sequencing the cellular DNA flanking viral insertion sites, the numerous 
independent insertions in individual tumors can be identified more comprehensively. 
Additionally, since integrated retroviruses can exert their effects over long distances due 
to enhancer elements, the assembled mouse genome allows for candidate genes that 
are distant to insertion site to be associated with that insertion event. Large-scale studies 
have now identified hundreds of unique insertion sites across panels of tumors, many of 
which are proximal to novel genes.  
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 High-throughput insertional mutagenesis screens have been used to look for 
genotype-specific interactions (Lund et al., 2002; Uren et al., 2008), and to identify new 
genes involved in specific pathways (Mikkers et al., 2002). As an example of the latter, 
one screen was designed to identify genes involved in the Pim-1 and Pim-2 pathways. 
Previously, the authors had performed a screen in Eµ-Myc Pim-1-/- animals. Since Pim-1 
is important in Eµ-Myc lymphomagenesis, insertion events that activate compensatory 
genes, either by genes downstream of Pim-1 or genes functioning in parallel pathways, 
would be expected to confer a selective advantage in tumor development. They found 
that retrovirus-mediated activation of the Pim-1 related gene, Pim-2, was observed in 
80% of Eµ-Myc Pim-1-/- lymphomas (van Lohuizen et al., 1991). To identify genes that 
compensate for Pim-1 and Pim-2 loss, the authors performed an insertional mutagenesis 
screen in Eµ-Myc Pim-1-/- Pim-2-/- mice, and found that Pim-3, as well as a number of 
other genes, were specifically upregulated by viral integrations in the absence of Pim-1 
and Pim-2, and therefore may function downstream or parallel to Pim-1 and Pim-2. 
Large-scale insertional mutagenesis screens have also been performed in Cdkn2a-/- 
mice (Lund et al., 2002), as well as p53-/- and p19Arf-/- animals (van Lohuizen et al., 
1991), to identify genes that are preferentially mutated on these genetic backgrounds. In 
the latter study, over 10,000 unique insertion sites from approximately 500 tumors were 
sequenced, with an average of over 20 unique insertions per mouse. With this number of 
independent insertion events, the authors were able to achieve the statistical power to 
necessary to determine if integration events occurred only in particular genetic 
backgrounds, or were found in the context of multiple genetic backgrounds. When only a 
subset of the integrations in each tumor are sequenced, integration sites that appear to 
be unique to a specific tumor genotype may actually be present in tumors of multiple 
genotypes, but may fail to be detected. Thus, improvements in sequencing technology 
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have facilitated the discovery of alterations that cooperate with specific genetic lesions in 
insertional mutagenesis screens.  
 While insertional mutagenesis screens have been very effective in identifying 
important genes that promote the initiation or progression of hematopoietic 
malignancies, this approach does have a several limitations. Insertional mutagenesis 
screens require positive selection for a given phenotype, generally tumor development. 
Consequently, negative selection screens, or screens that identify genes, via gain or loss 
of function, that negatively impact a disease process, have not been performed.  
 Additionally, gain of function mutations in oncogenes, rather than loss of function 
mutations in tumor suppressor genes, preferentially undergo positive selection in 
insertional mutagenesis screens. A single viral integration event proximal to an 
oncogene is sufficient to confer a selective advantage in these screens, whereas two 
independent viral integration events are required to disrupt both alleles of a tumor 
suppressor gene, and therefore, tumor suppressor genes are rarely identified in 
insertional mutagenesis screens. Only 10% of common viral insertion events were 
predicted to disrupt gene function in one large-scale screen (Suzuki et al., 2002), and in 
these cases, it was unclear if disrupted gene products were actually truncated oncogenic 
proteins lacking regulatory domains, rather than inactivated genes. In cases of mono-
allelic inactivation, disrupted genes may represent haploinsufficient tumor suppressors. 
One of the few instances where viral inactivation of a tumor suppressor has been 
observed is in Nf1; in these tumors, the wildtype Nf1 transcript could not be detected, 
suggesting that the gene had undergone bi-allelic inactivation, either by viral integration 
into both alleles, or by epigenetic silencing or mutation of the wildtype allele 
(Largaespada et al., 1995). To facilitate the identification of tumor suppressor genes, one 
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group performed an insertional mutagenesis screen in a Blm-deficient background. In 
this context, the frequency of heterozygous gene inactivation events becoming 
homozygous is increased, due to increased rates of mitotic recombination between non-
sister chromatids. Even on this sensitized background, the majority of common insertion 
sites were predicted to activate, rather than disrupt, gene expression. However, the 
authors identified a number of viral integration events in the coding regions of genes that 
had become homozygous, and that were accompanied by decreased transcript levels of 
the target gene, strongly suggesting that these integration events had occurred in tumor 
suppressors (Suzuki et al., 2006).  
 Additional challenges arise in identifying common insertion sites. Murine 
leukemia viruses preferentially insert into transcribed genes, near transcriptional start 
sites (Berry et al., 2006; Wu et al., 2003). When a background distribution of random 
viral integrations throughout the genome is assumed, clustering of insertion events in 
these genomic locations can result in false positives. Identification of putative 
oncogenes, or the genes that are impacted by common insertion events, is also difficult. 
Because viral enhancer elements can act over long distances (Lazo et al., 1990), viruses 
may increase the expression of distant genes, rather than the most proximal gene. To 
systematically identify virally deregulated genes, one group looked at the transcript 
levels of all genes within 100 kb of common insertion sites across a panel of tumors. For 
about 50% of insertion sites, they could not identify a deregulated gene within this 
window, and for other insertion sites, they found that multiple genes were often 
deregulated and that genes far from the insertion sites were overexpressed as frequently 
as proximal genes (Sauvageau et al., 2008).    
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 Candidate genes identified in insertional mutagenesis screens require 
experimental validation to show that they are bona fide oncogenes, or more infrequently, 
tumor suppressors. Traditionally, this has been done by making transgenic mice, and 
showing that a gene accelerates tumor development (Alkema et al., 1997; Haupt et al., 
1993; Verbeek et al., 1991). Now that individual screens can identify hundreds of 
common insertion sites, testing candidates on a gene-by-gene basis is becoming 
increasingly difficult. These screens rely on the re-identification of known oncogenes to 
validate the quality of the datasets, and then comparison of screening data, human 
mutational data, and tumor copy number alteration data to identify potentially interesting 
and novel genes. However, without assays to rapidly assess the phenotypic impact of 
overexpression of candidate genes, the identification of functionally important genes 
within these large datasets remains challenging.    
 Additionally, viral tropisms limit the types of tumors that can be studied in 
insertional mutagenesis screens. To produce a tumor, a virus must be able to infect a 
tissue, be expressed at high levels, and replicate within that tissue. Even within the 
hematopoietic system, different leukemia viruses produce tumors in distinct cell lineages; 
Graffi-type viruses usually produce myeloid malignancies (Erkeland et al., 2004), 
whereas Moloney viruses produce T cell malignancies, unless screens are performed on 
genetic backgrounds that are predisposed to B cell malignancies. In addition to the 
hematopoietic system, insertional mutagenesis screens have also been performed in the 
mammary gland, which can be infected by the mouse mammary tumor virus (MMTV). In 
these tumors, insertions proximal to Fgf and Wnt family members are frequently 
observed (Dickson et al., 1984; Nusse and Varmus, 1982; Peters et al., 1983; 
Theodorou et al., 2007). In another solid tumor model, one group initiated gliomas by 
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infecting the brains of mice with a Moloney MLV engineered to express PDGF, and 
identified a number of candidate genes that may cooperate with PDGF in tumorigenesis 
based on common insertion sites (Johansson et al., 2004; Uhrbom et al., 1998). Thus, 
while used in small number of non-hematopoietic tumors, insertional mutagenesis 
screens have not been broadly adapted to solid tumors.  
 
Transposon-based in vivo screens in hematopoietic and non-hematopoieitic 
tissues 
 More recently, systems to perform in vivo transposon-based insertional 
mutagenesis screens have been developed. Unlike retroviral insertional mutagenesis 
screens, transposon-based mutagenesis screens can be performed in a broad array of 
tissue types. These screens make use of a bipartite system, where transgenic mice are 
generated that express concatemers of a mobile element, the transposon, and, in trans, 
the transposase, which is an enzyme that can mobilize the transposon. Once mobilized, 
transposons will re-integrate throughout the genome and can alter gene function. 
 The reactivation of an ancient Tcl/mariner transposon has made transposon-
based screens possible. This family of transposons is one of the most widespread, 
which suggested that family members may be less dependent on species-specific host 
factors, and therefore, if reactivated, might function in a range of host cells. By 
comparing sequences of twelve inactive salmanoid-type transposons, which are the 
youngest and most recently active transposons in the Tcl/mariner family, a consensus 
sequence for the active transposon was derived. From this consensus sequence, an 
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active transposase, termed Sleeping Beauty, was engineered and found to function in 
mouse and human cells (Ivics et al., 1997). 
 In transposon screens, mice expressing the active Sleeping Beauty transposase 
are crossed to animals that have germline-integrated concatemers of transposons. 
Transposons are designed to contain polyadenylation sequences and splice acceptors, 
so insertion events can disrupt the function of tumor suppressor genes, as well as a viral 
LTR and splice donor cassette, allowing these elements to drive the expression of 
proximal proto-oncogenes. By expressing multiple copies of transposons in animals, the 
frequency of tumorigenic reintegration events increases. Once tumors arise, transposon 
junctions are PCR amplified and sequenced, and genes that are altered by transposons 
in multiple tumors are considered candidate oncogenes or tumor suppressors.  
 In one of the first in vivo transposon screens, crosses between transgenic mice 
ubiquitously expressing an active transposase and animals with concatemers of 150-300 
copies of a mutagenic transposon produced offspring that rapidly developed 
malignancies. Hematopoietic malignancies predominated, the majority of which were T 
cell lymphomas, although a small number of neoplasms and tumors were observed in 
other tissues (Dupuy et al., 2005). In another screen published at the same time, mice 
harboring fewer copies (approximately 25) of a transposon were crossed to transpoase-
expressing animals. Although no tumors developed in wildtype mice, soft tissue 
sarcomas did develop on a sensitized Arf-/- background at an accelerated rate (Collier et 
al., 2005). These studies identified frequent insertions in known oncogenes; activating 
Notch mutations were observed in T cell malignancies, and activating Braf mutations 
were seen in sarcomas.  
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 While this initial work demonstrated the feasibility of using transposons for in vivo 
screens, they either primarily produced hematopoietic malignancies, or failed to produce 
tumors on non-sensitized genetic backgrounds. Subsequent modifications to these 
screens expanded the spectrum of tumors that could be studied. Alterations to the viral 
promoter within transposons were sufficient to change the tumor spectrum when 
combined with a ubiquitously expressed transposase; by replacing the MSCV LTR, 
which is highly expressed in hematopoietic cells, with a CAG promoter, which is 
expressed in a variety of tissue types, squamous cell carcinomas and hepatocellular 
carcinomas developed, rather than T cell malignancies (Dupuy et al., 2009).  To 
precisely control the tumor spectrum in transposon screens, conditional systems have 
been developed, where the Sleeping Beauty transposase is floxed by lox-stop-lox sites. 
These mice have been crossed with animals expressing a tissue specific Cre-
recomibinase, restricting transposase expression to target tissues. When villin-Cre was 
used to activate transposase expression in the gastrointestinal tract, intestinal 
neoplasias and adenomas developed, and the human colorectal cancer gene APC was 
frequently inactivated by transposon insertions (Starr et al., 2009). By crossing lox-stop-
lox transposase animals with mice expressing the hepatocyte-specific albumin-Cre, 
transposition events were limited to the liver, resulting in the formation of pre-neoplastic 
nodules in this organ. In these nodules, Egfr was frequently truncated by transposon 
insertions, and a number of novel common insertion sites were also identified (Keng et 
al., 2009). 
 The moth transposon PiggyBac has also been reactivated and shown to be 
functional in mammalian cells and in transgenic mice (Ding et al., 2005). When PiggyBac 
transposase mice were crossed to a number of different transposon lines, which varied 
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both in transposon copy number and the viral promoter contained within the transposon, 
double transgenic offspring developed hematopoietic and solid tumors. Similar to 
previous studies, the viral promoter skewed the tumor distribution; tumors with 
transposons containing the MSCV LTR were primarily hematopoietic, and transposons 
with the CAG promoter produced solid tumors. When common insertion sites from 
PiggyBac or Sleeping Beauty hematopoietic tumors were compared, a large proportion 
of these sites were novel to the PiggyBac system, suggesting that these two 
transposons may have different integration preferences. Thus, the range of mutations 
identified in transposon screens may be expanded by using multiple transposition 
systems (Rad et al., 2010). 
 Using transposon mutagenesis approaches, in vivo screens can be performed in 
a broad array of tissues. In addition to identifying genes that promote tumorigenesis in 
solid and hematopoietic malignancies, they have also been used to identify mutations 
that cooperate with established oncogenic lesions. For example, in the intestine, 
transposon screens have been performed in mice with APC mutations (March et al., 
2011). One group showed that a mutation in the gene Nucleophosmin, which is mutated 
in human acute myeloid leukemia (AML), produces AML in mice with a protracted 
latency, and used transposon screens to identify cooperating alterations that accelerate 
disease development (Vassiliou et al., 2011). 
 While these screens have been very effective, they share a number of limitations 
with insertional mutagenesis screens. Like insertional mutagenesis screens, transposon 
screens are primarily positive selection screens. They identify genes, that when 
deregulated, promote tumor development, rather than genes that can negatively impact 
this process. Thus, they are useful in elucidating novel pathways that are important for 
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tumorigenesis, but cannot directly identify genes whose loss can impair tumor growth 
and progression, particularly in established tumors. Additionally, while transposons are 
designed to be able to disrupt the function of tumor suppressors and enhance the 
expression of proto-oncogenes, they are still biased towards the identification of 
oncogenes, since gain of function alterations require integration in only one allele of a 
gene, whereas inactivation of tumor suppressors requires bi-allelic transposon 
insertions. In intestinal lesions, insertions in the knows tumor suppressors Pten, Smad4, 
and Bmpr1a have been identified, without inactivation of the other allele, indicating that 
these genes may be haploinsufficient tumor suppressors in this disease, or that the 
second allele is inactivated by an alternative mechanism (March et al., 2011). 
Additionally, bi-allelic inactivation of Pten has been observed hematopoietic tumors (Rad 
et al., 2010); however, these bi-allelic events are expected to be far less frequent than 
the activation of oncogenes. 
 The Sleeping Beauty transposon was shown to have relatively little insertional 
bias when a large number of insertion sites were mapped. Excluding the chromosome 
carrying the concatemers of transposons, where local hopping events frequently occur, 
insertion sites were widely distributed throughout the genome, although there were local 
preferences for AT-rich regions. Insertion events were slightly biased towards 
transcribed genes, but significantly less so than viruses (Yant et al., 2005). Thus, the 
identification of common insertion sites should be simplified in these screens, since a 
relatively uniform background insertion rate can be assumed. However, the large 
number of non-overlapping common integration sites in PiggyBac and Sleeping Beauty 
hematopoietic tumors would suggest that some integration biases do exist, and these 
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are dependent on the specific transposon used, which could lead to the false 
identification of common insertion sites.  
 Like insertional mutagenesis screens, transposon screens generate large 
numbers of putative hits. Often, the most frequently altered genes are known 
oncogenes. Using these genes as controls for the quality of the overall dataset, 
oncogenic pathways and networks are then built based on the set of putative hits 
identified, to reduce the complex gene sets to a coherent biology. Alternatively, these 
screens rely on comparisons with other datasets, like tumor mutational or transcriptional 
data, to suggest that less well-established candidate hits have a causative role in 
disease development. However, new genes are rarely functionally validated, particularly 
in in vivo tumor models, making it unclear if the majority of genes identified in these 
screens are important in tumorigenesis. 
 
RNAi-based screens in mammalian cells  
 The more recent utilization of RNA interference (RNAi) in mammalian systems 
has allowed for the systematic interrogation of the impact of the loss of function of genes 
in mouse and human cell lines. Initially delivered as chemically synthesized 21mer 
siRNA duplexes, RNAi constructs were shown to effectively silence target genes in 
mammalian cells (Caplen et al., 2001; Elbashir et al., 2001). To achieve stable, rather 
than transient suppression of target genes, these duplexes were modified and expressed 
endogenously as short-hairpin RNAs composed of a stem-loop structure (Brummelkamp 
et al., 2002; Paddison et al., 2002; Sui et al., 2002; Yu et al., 2002). To simultaneously 
assess the impact of the loss of function of large sets of genes and aid in the discovery 
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of novel genes involved in disease processes, libraries of shRNAs were generated that 
targeted the human and mouse genomes in an unbiased manner. Initially, these libraries 
were composed of short shRNA duplexes expressed from the RNA polymerase III 
promoter (Berns et al., 2004; Brummelkamp et al., 2003; Paddison et al., 2004). Based 
on observations that shRNAs embedded within the full-length mir30 transcript were 
processed to mature stem-loop structures by endogenous microRNA machinery and 
effectively silenced their target genes (Zeng et al., 2002), and that expression of shRNAs 
within this context resulted in increased levels of mature shRNAs, new libraries were 
synthesized using this shRNA design (Silva et al., 2005). Additionally, by expressing 
these shRNAs from the RNA polymerase II promoter, single copy genomic integration 
events were found to be sufficient to silence target genes, and gene silencing was 
largely independent of the site of integration (Dickins et al., 2005; Stegmeier et al., 
2005).  
 shRNA screens can be performed using either pool-based or arrayed 
approaches. In pooled screens, populations of cells are infected with a pooled shRNA 
library, and the enrichment or depletion of particular shRNAs within this bulk infected 
population is used as a readout of the impact of gene suppression on a cellular process. 
Arrayed screens rely on the infection of individual populations of cells with single shRNA 
constructs, typically in 96 or 384 well plates. These shRNA-infected cells are then 
monitored for phenotypic alterations. In one of the first unbiased shRNA screens, a pool-
based based approach was used to identify genes that can overcome p53-mediated 
growth arrest. Here, cells were infected with a large pool of shRNAs, and only cells 
containing hairpins that promoted the bypass of p53-mediated arrest were able to 
proliferate, suggesting that genes targeted by these hairpins function in the p53 pathway 
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(Berns et al., 2004). In other early shRNA screening work, arrayed screens were 
performed to validate large-scale shRNA libraries. These screens were designed to 
identify genes that are necessary for the proteosome-mediated degradation of proteins. 
Here, individual shRNAs were co-transfected with a fluorescently tagged protein 
containing a degradation signal, and shRNAs that interfered with this process were 
identified by an increase in florescence in infected cell populations (Paddison et al., 
2004; Silva et al., 2005).  
 The discovery of genes that are important in cancer has been aided by shRNA 
screening approaches. Because shRNAs mimic gene loss of function events, these 
screens can be used to identify novel tumor suppressors. One method of identifying 
tumor suppressors has been to perform pool-based screens in partially transformed cell 
lines. In one screen, an unbiased library of shRNAs was introduced into mammary 
epithelial cells that express hTERT, the large T antigen of SV40, and high levels of Myc. 
This set of genetic alterations is not sufficient for anchorage-independent growth, a 
property that is indicative of transformation, but the addition of hairpins targeting a tumor 
suppressor can cause cells to grow in an anchorage-independent fashion. Here, 
transduction of partially transformed cells with an shRNA library and sequencing of 
hairpins that promoted transformation identified the gene REST as a tumor suppressor 
(Westbrook et al., 2005). Another tumor suppressor screen was performed in a partially 
transformed fibroblast cell line. In this line, the expression of hTERT, small T antigen, 
oncogenic RasV12, and suppression of p53 and p16 causes transformation. By omitting 
RasV12, and introducing libraries of shRNAs, the authors identified a number of hairpins 
that could substitute for RasV12  expression in transformation, and identified PITX1 as a 
regulator of Ras signaliing (Kolfschoten et al., 2005). These screens demonstrate how 
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positive selection for a transformed phenotype can facilitate the identification of tumor 
suppressor genes in pool-based screens. 
 Pool-based negative selection shRNA screens have been used to identify 
putative drug targets in cancer cells. In these screens, shRNAs that adversely impact a 
cellular process, like proliferation or survival, are identified by a relative decrease in the 
abundance of those shRNAs. Initially, the abundance of shRNAs was quantified using 
microarrays. Here, either a unique barcode was attached to each shRNA, or the unique 
sequence of each hairpin was used as a molecular tag, and this unique region was PCR 
amplified from genomic DNA and hybridized to custom arrays containing the bar-coded 
oligonucleotides (Berns et al., 2004; Ngo et al., 2006; Paddison et al., 2004; Westbrook 
et al., 2005). Now, these amplified shRNAs can be directly sequenced and quantified 
using high-throughput approaches. In one example of a sensitization screen, shRNAs 
that negatively impacted two types of diffuse large B cell lymphomas were compared. 
Here, a pool of inducible shRNAs targeting approximately 2500 genes were introduced 
into activated B-cell like lymphomas and germinal center B cell lymphomas, which have 
distinct molecular profiles and genetic dependencies. Following a period of in vitro 
proliferation, shRNA abundance was quantified and used to identify genes that 
specifically impaired activated B-cell like lymphomas. Here, CARD11 was shown to be a 
modulator of activated B-cell like lymphoma growth (Ngo et al., 2006). Other large-scale 
negative selection screens have been performed using libraries targeting signaling 
regulators and genes in cancer-related pathways (Schlabach et al., 2008), as well as 
unbiased shRNA sets (Silva et al., 2008). By comparing different cell lines, these 
screens have identified shRNAs that were generally required for cancer cell viability and 
growth, as well as cell-line specific genetic dependencies. 
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 shRNA screens have also been used to devise novel therapeutic approaches 
and to exploit specific cancer cell vulnerabilities. In synthetic lethal screens, groups have 
identified shRNAs that are toxic in cell lines expressing oncogenic Ras, but not cell lines 
with wildtype Ras, which include hairpins targeting regulators of mitotic progression (Luo 
et al., 2009) and regulators of NFκB signaling (Barbie et al., 2009), and pharmacological 
inhibition of these gene products may represent a therapeutic strategy in Ras mutant 
tumors. shRNA screens have also been used to study chemotherapeutic response in 
cancer cells, both to identify genes that are necessary for the action of drugs 
(Brummelkamp et al., 2006; Swanton et al., 2007), and to identify genes whose 
suppression sensitizes cells to therapy (Whitehurst et al., 2007). Additionally, shRNA 
screens have been performed that examine more complex aspects of cancer 
progression, like migration and invasion (Simpson et al., 2008). One genome-wide pool 
based shRNA screen identified a set of hairpins that increased cell migration into an 
extracellular matrix, as well as cell survival and proliferation within this matrix, using a 
three-dimensional culture system, and found that candidate hits from this screen also 
increased lung metastasis in in vivo assays (Gobeil et al., 2008). Thus, shRNA screens 
have been used to identify genes that impact diverse processes in cancer cells.   
 By using shRNA screens, the impact of the loss of function of large numbers of 
genes can be simultaneously assayed. While early pool-based screens were positive 
selection screens, relying on the outgrowth of rare cells under growth-inhibitory 
conditions, methods to deconvolute shRNA representation have made negative selection 
screens possible. Bulk populations of cells can be infected with large pools of shRNAs, 
and hairpins that increase or decrease in representation after a period of growth, relative 
to an input population, can be detected using microarray or high-throughput sequencing 
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approaches. Additionally, improvements in high-throughput sequencing technology are 
now providing sufficient resolution to detect more subtle changes in shRNA 
representation in these screens. In contrast to insertional mutagenesis screens, scoring 
candidates in shRNA screens can be rapidly functionally validated. By re-introducing 
scoring shRNAs into cells as a single constructs, as well as additional shRNAs targeting 
the same gene, it is possible to easily assess if suppression of candidate genes 
recapitulates the screening phenotype. This greatly facilitates assigning candidate hits 
roles in biological processes.  
 
In vivo pool-based shRNA screens in hematopoietic malignancies 
 Unlike viral insertional mutagenesis and transposon screens, shRNA based 
screens have primarily been performed in vitro, rather than in vivo. While they have 
effectively identified a large number of genes that are important for cancer cell 
proliferation and survival, in vitro screens fail to accurately mimic the physiological 
context of normal tumor growth. Due to local cues that can alter the growth and survival 
requirements of tumor cells, the genetic dependencies of cancer cells in vivo might differ 
from those in vitro. Thus, devising in vivo shRNA screening strategies could reveal novel 
genes and pathways that impact tumor progression. 
 The work presented in this thesis describes the adaptation of pool-based shRNA 
screening approaches to in vivo applications. Specifically, I have made use of 
transplantable models of hematopoietic malignancies to screen for modulators of tumor 
cell growth in vivo. Both normal cells of the hematopoietic system, as well as 
hematopoietic tumors, can be isolated from donor mice, manipulated ex vivo, and 
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transplanted into recipient animals, suggesting that cells from this system might be 
amenable to transduction with shRNA libraries. Historically, retroviral manipulations of 
hematopoietic cells have been used to mark and track stem and progenitor cell 
populations. Early work showed that it was possible to harvest whole bone marrow from 
donor animals and culture these cells under conditions that promoted retroviral infection 
of progenitor cells (Joyner et al., 1983). Following transplantation, infected progenitor 
cells gave rise to differentiated cells in both the myeloid and lymphoid lineages in 
recipient animals, suggesting that manipulated progenitor cells can both engraft and 
contribute to normal hematopoiesis (Capel et al., 1989; Dick et al., 1985; Keller et al., 
1985; Lemischka et al., 1986; Miller et al., 1984; Williams et al., 1984). Retroviral 
infections of whole bone marrow have also been used to model hematopoietic diseases 
in mice; by transducing this cell population with a construct expressing the Bcr-Abl fusion 
protein and transplanting infected cells into recipient animals, it has been possible to 
produce a chronic myeloid leukemia-like disease (Daley et al., 1990; Pear et al., 1998). 
Similar approaches have been used to generate transplantable models of acute myeloid 
leukemia and acute lymphoblastic leukemia. Transplantation of fetal liver HSCs 
transduced with MLL fusion proteins or the AML/ETO fusion protein produces AML in 
recipient animals (Zuber et al., 2009), and transplantation of pre-B cells transduced with 
Bcr-Abl produces ALL in recipient mice (Williams et al., 2007; Williams et al., 2006). 
 Cells from established hematopoietic tumors can also be infected ex vivo and 
then transplanted into secondary syngeneic recipient mice. Transplantation of primary 
Eµ-myc tumors, which are B cell lymphomas driven by high levels of Myc expression 
and model human Burkitt’s lymphoma (Adams et al., 1985), produces secondary tumors 
that are pathologically indistinguishable from the original tumors, suggesting that tumor 
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growth in transplanted disease can accurately recapitulate many aspects of the primary 
tumor. Importantly, retroviral manipulations of these tumors have allowed defined genetic 
alterations to be studied in the in vivo context. For example, ex vivo introduction of the 
anti-apoptotic protein Bcl2 produces chemoresistant Eµ-myc tumors upon 
transplantation (Schmitt et al., 2000), and transduction of tumor cells with Bcl2 or a 
dominant negative Caspase9 construct provides a selective growth advantage in vivo 
(Schmitt et al., 2002). Additionally, shRNA-mediated gene suppression can be used to 
effectively mimic gene loss of function events in tumors in vivo; transplantation of Eµ-
myc fetal liver cells transduced with hairpins targeting p53 accelerates tumor onset, 
mimicking the impact of p53 loss (Hemann et al., 2003), and infection and 
transplantation of primary tumor cells with shRNAs targeting p53, Topoisomerase1, and 
Topoisomerase2a impact chemotherapeutic outcome in secondary malignancies 
(Burgess et al., 2008). Together, these results suggested that, by introducing pools of 
shRNAs into lymphoma cells and transplanting transduced cells to recipient mice, it 
might be possible to assay the impact of large sets of genetic lesions on tumor growth 
and perform loss of function screens in vivo.  
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Abstract 
  
 Mouse models have dramatically improved our understanding of cancer 
development and tumor biology.  However, these models have shown limited efficacy as 
tractable systems for unbiased genetic experimentation.  Here, we report the adaptation 
of loss of function screening to mouse models of cancer. Specifically, we have been able 
to introduce a library of shRNAs into individual mice using transplantable Eµ-myc 
lymphoma cells.  This approach has allowed us to screen nearly 1000 genetic alterations 
in the context of a single tumor-bearing mouse.  Results from these experiments have 
identified a central role for regulators of actin dynamics and cell motility in lymphoma cell 
homeostasis in vivo, and validation experiments confirmed that these proteins represent 
bona fide lymphoma drug targets.  Additionally, suppression of two of these targets, 
Rac2 and Twinfilin, potentiated the action of the front-line chemotherapeutic vincristine, 
suggesting a critical relationship between cell motility and tumor relapse in hematopoietic 
malignancies.  
 
Introduction 
Genetic screens in the mouse hematopoietic system have proven to be highly 
effective strategies for identifying novel and cooperating cancer genes.  For example, 
Moloney-based retroviral insertional mutagenesis screens first characterized the potent 
oncogenes bmi-1 and pims 1-3 (Jonkers and Berns, 1996; van Lohuizen et al., 1991).  
Subsequently, these screens have been performed on numerous sensitized 
backgrounds, revealing significant insight into the relationship between specific 
oncogenic and tumor suppressor alterations (Uren et al., 2008).  The more recent 
development of mice expressing active transposons has similarly facilitated the 
identification of novel cancer genes (Collier et al., 2005; Dupuy et al., 2005; Suzuki et al., 
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2006). While these approaches have been highly successful, they have several notable 
limitations.  First, genes affected by insertional mutagenesis are identified as likely 
candidates based on proximity to the insertion site.  Thus, numerous mice are required 
to identify “common insertion sites”, and affected genes need to be functionally 
validated.  Second, despite the use of highly recombinant genetic backgrounds, the 
identification of relevant tumor suppressor genes by insertional mutagenesis is 
inefficient.  Finally, insertional mutagenesis requires positive selection for a given 
phenotype, generally tumor development.  Thus, sensitization screens based on the 
selective depletion of a given insertion site cannot be performed. 
 
We have recently adapted miRNA-based shRNA gene silencing to in vivo 
applications in the Eµ-myc lymphoma mouse, a well-established model of B cell 
lymphoma (Adams et al., 1985; Dickins et al., 2005; Hemann et al., 2003). This 
approach has subsequently been expanded to examine small sets of shRNAs in a cohort 
of mice (Zender et al., 2008).  However, despite the disseminated and effective use of 
cell-based RNAi screens (Berns et al., 2004; Firestein et al., 2008; Grueneberg et al., 
2008; Luo et al., 2008; Ngo et al., 2006; Schlabach et al., 2008; Westbrook et al., 2005), 
adaptation of these approaches to mouse models has been limited.  Here, we use RNAi 
to interrogate loss of function phenotypes for large gene sets in the context of individual 
mice. Results from this study identify a set of genes involved in cytoskeletal organization 
and cell migration that are important for lymphoma progression in vivo.  Importantly, this 
study demarcates critical determinants of tumor behavior in vivo, information that could 
not be obtained using conventional cell-based screening approaches.  
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Results and Discussion 
 Previous studies in the Eµ-myc system have suggested that Eµ-myc lymphomas 
are largely composed of cells with tumor initiating potential.  Specifically, tumor cell 
dilution experiments have shown that as few as 10 tumor cells can produce tumors 
following tail vein injection into syngeneic recipient mice (Kelly et al., 2007).  Thus, we 
reasoned that if nearly all tumor cells have the capacity to contribute to tumor formation 
following transplantation, then this system might accommodate the introduction of a 
diverse set of shRNA-infected cells into a given tumor.  To test this, we performed a 
dilution experiment using lymphoma cell cultures that were partially transduced with a 
retroviral vector co-expressing an shRNA targeting Topoisomerase 2α (Top2A), an 
essential mediator of the cytotoxic effects of the chemotherapeutic doxorubicin (Burgess 
et al., 2008), and the gene encoding Green Fluorescent Protein (GFP) to mark infected 
cells. Viral multiplicity of infection (MOI) was titered, such that either 2.0% or 0.2% of 
lymphoma cells were infected. These partially transduced lymphoma cell populations 
were injected into syngeneic recipient mice, and mice were treated with doxorubicin at 
the time of lymphoma presentation. At both infection efficiencies, we saw a significant 
increase in the percentage of GFP-positive cells following treatment (Fig. 1a). These 
results showed that cells representing as little as 1/500th of the injected lymphoma cell 
population were retained at the time of doxorubicin treatment. These data are consistent 
with large numbers of lymphoma cells (at least 500) contributing to an individual tumor 
following transplantation in vivo, and suggest the Eµ-myc lymphoma model may be 
appropriate for in vivo, pool-based RNAi screens with complex shRNA libraries.  
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Based on these preliminary results, we performed an shRNA screen with a pool 
of approximately 2250 hairpins targeting 1000 genes with known or putative roles in 
cancer (Burgess et al., 2008). Retroviral plasmids expressing these shRNAs, as well as 
GFP, were pooled and packaged as a mixture of retroviruses.  This retroviral pool was 
then used to infect lymphoma cells, and the resulting transduced cells were injected into 
recipient mice, maintained in culture, or collected immediately to serve as a reference 
sample (Fig. 1b). At the time of lymphoma presentation, tumors were harvested and 
genomic DNA was extracted from primary tumors and cultured cells. Following PCR 
amplification of shRNAs from genomic DNA using common primers (Fig. 1b), hairpin 
representation was analyzed by high throughput sequencing. 
 
Approximately 1600 of the original 2250 unique hairpins could be identified from 
each in vitro cultured sample, and, surprisingly, between 600 and 900 unique hairpins 
could be identified in lymphomas from individual mice (Fig. 1c).  Thus, a large, diverse 
shRNA set can be introduced in vivo and a significant proportion of the initial library 
complexity can be maintained in this setting.  Sequencing of shRNAs from genomic DNA 
derived from outgrown single cell clones showed that approximately 90% of cells were 
infected with only a single shRNA (Supplementary Fig. 1), suggesting that, at a 
minimum, 900 cells can contribute to the lymphoma burden in an individual mouse.  
Thus, not only can a large percentage of lymphoma cells give rise to a tumor following 
transplantation, but, in fact, many of these cells contribute to the growth of the resulting 
tumor. 
 
Unsupervised hierarchical clustering showed that the three in vivo samples were 
more similar to one another than to any of the cultured in vitro samples, based on the 
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hairpins that enriched or depleted in each setting (Fig. 1d).  Thus, the set of genes that 
impacts cancer cell homeostasis in vitro is distinct from those that are central to tumor 
growth in vivo. Importantly, the number of sequencing reads obtained was sufficient to 
see both enrichment and depletion of shRNAs from the initial injected population.  While 
many shRNAs displayed similar changes in representation in clustered samples, 
significant variation was also present in samples of the same type.  This is likely due to 
the stochastic gain or loss of shRNAs following introduction into mice or serial re-plating 
in culture.  
 
Hairpins whose representation decreased at least 10-fold in all three replicates or 
enriched at least 5-fold in two out of three replicates, relative to their representation in 
the control cell population collected shortly after retroviral transduction, scored as 
candidate hits. The set of scoring shRNAs in vitro by this criteria was largely non-
overlapping with the set of shRNAs that scored in vivo (Fig. 1e, Supplementary Table 1), 
indicating that by performing shRNA screens in the context of a normal tumor 
microenviroment, we were able to identify a set of genes that exclusively impacts growth 
in a physiologically relevant setting. 
 
 We focused our follow-up studies on shRNA sets that specifically affected tumor 
growth in vivo.  As a more stringent criterion, we selected genes for which 2 or more 
cognate shRNAs depleted on average at least 10-fold in mice (Table 1). Based on gene 
ontology (GO) classifications and manual curation, shRNAs targeting genes involved in 
cell motility, including dynamic actin reorganization and cell adhesion, were highly 
represented in the set of hairpins that specifically depleted in vivo (8 out of 11).  Several 
of these genes were chosen for validation (Supplementary Fig. 2a).  These included 
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genes encoding Rac2, a hematopoetic-specific Rho GTPase important for the formation 
of lamellipodia during cell migration (Burridge and Wennerberg, 2004; Ridley et al., 
1992), CrkL, an adaptor protein reported to be involved in the activation of Rac 
(Nishihara et al., 2002), and Twinfilin (Twf1), an actin monomer-binding and actin 
filament capping protein (Helfer et al., 2006). For these genes, multiple independent 
shRNAs (Fig. 2a) recapitulated the initial screening phenotype. Specifically, while cells 
grown in the presence of these shRNAs grew robustly in culture, they all showed a 
selective depletion in lymph nodes following tail vein injection (Fig. 2b). To further 
characterize the efficiency of our screen, we examined a non-motility gene targeted by 
two depleted shRNAs and two genes targeted by a single scoring shRNA.  shRNAs 
targeting the genes encoding IL-6 (two depleted shRNAs in our screen) and Lyn kinase 
(one depleted shRNA in our screen) depleted following introduction in mice, while 
shRNAs targeting the gene encoding AIF-1 (one depleted shRNA in our screen) failed to 
deplete (Supplementary Fig. 2b and data not shown).  Thus, shRNAs targeting four out 
of four genes from the gene set identified using our most stringent criteria validated as 
single constructs, while the validation rate for single scoring shRNAs was lower.  
 
To further characterize the role of genes identified in our screen in lymphoma 
homeostasis, we subjected shRNA-infected cells to secondary functional assays.  
Lymphoma cells suppressing Rac2, CrkL, or Twf1 showed motility defects in transwell 
migration assays, consistent with a role for these proteins in lymphoma cell migration 
(Fig. 2c and d and Supplementary Fig. 3a and b). Additionally, Rac2-deficient lymphoma 
cells showed defects in SDF-1α induced migration on fibronectin (Supplementary Movies 
1 and 2).  Suppression of Rac2 also resulted in impaired lymphoma cell migration in 
short term in vivo engraftment assays. Specifically, lymphoma cells suppressing Rac2 
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were depleted in the spleen and bone marrow two and twenty-four hours after tail vein 
injection (Fig. 3a).  Similar to the effect Rac2 knockdown, lymphoma cells suppressing 
Wave2, an important mediator of cell migration known to function downstream of other 
Rac proteins (Smith and Li, 2004), showed chemotaxis defects in vitro and were 
selectively depleted in the lymph nodes at the time of disease presentation (Fig. 3b and 
Supplementary Fig. 3c and d).  
 
Suppression of Rac2 was also selected against in common sites of lymphoid 
metastasis, such as the liver, as seen by histology and by GFP enrichment analysis 
(Figs. 3c and d), suggesting that Rac2 might represent a meaningful lymphoma drug 
target.  In fact, suppression of Rac2 in lymphoma cells extended both tumor free and 
overall survival following tail vein injection (Fig. 3e and f). Similarly, lymphoma-bearing 
mice treated with NSC23766 (Gao et al., 2004), an inhibitor of Rac1 and Rac2 
(Supplementary Fig. 4a) (Cancelas et al., 2005), survived significantly longer than 
untreated controls (Fig. 4a). Notably, suppression of Twf1 also delayed tumor 
progression following lymphoma tail vein injection (Supplementary Fig. 4b).  Thus, 
multiple proteins involved in actin reorganization and cell motility represent potential drug 
targets in B cell malignancies.  Additionally, combinations of shRNAs produced 
synergistic effects on lymphoma growth (Supplementary Fig. 4c).  
 
Interestingly, when lymphomas were treated with the chemotherapeutic 
vincristine, knockdown of Rac2 or Twf1 extended animal survival following drug 
treatment (Fig. 4b and Supplementary Fig. 4d). Importantly, this effect was specific for 
therapeutic response in vivo, as suppression of Rac2 did not sensitize lymphoma cells to 
vincristine treatment in culture (data not shown). These results suggest that there is a 
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requirement for tumor cell mobilization in lymphoma relapse and that Rac2 and Twf1 
activity is important in this mobilization (Fig. 4c).  It further suggests that Rac2 or Twf1 
inhibition, or inhibition of lymphoma cell motility by another mechanism, may synergize 
with conventional chemotherapeutics in the treatment of lymphoma. 
 
Using a well-established mouse model of B cell lymphoma, we have adapted 
RNAi screens to in vivo applications. With this system, we were able to screen over 900 
unique hairpins in individual mice.  While improvements in RNAi technology will be 
required to perform saturating loss of function studies, this work demonstrates the 
feasibility of using large, unbiased shRNA sets for in vivo screens.  Importantly, unlike 
conventional microarray studies, this approach investigates gene function, rather than 
gene expression – implicating “scoring” genes as directly relevant to interrogated 
phenotypes. We can envision using a similar approach to examine modulators of 
therapeutic response or tissue-specific tumor dissemination.  Importantly, identification of 
similarly tractable genetic systems may permit the adaptation of this screening 
methodology to study tissue development or the biology of solid tumors. 
 
Our screen identified modulators of lymphoma cell motility and chemotaxis as 
key determinants of tumor homeostasis.  This group included known regulators of actin-
based cell motility, as well as proteins, like Twf1, with known roles in actin dynamics but 
no established role in mammalian cell migration.  Suppression of Rac2 and Twf1 in 
lymphoma cells impaired lymphoma cell migration to the lymph nodes and other organs 
that represent common sites of lymphoid metastasis.  Additionally, pharmacological 
inhibition of Rac2 synergized with a conventional chemotherapeutic to extend the 
lifespan of tumor-bearing mice. These results highlight a potential therapeutic strategy in 
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hematopoietic cancers, suggesting that, in instances where there is minimal metastasis 
at the time of initial treatment with traditional chemotherapeutics, suppression of cell 
migration may improve therapeutic outcome. 
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Materials and Methods 
 
 
Cell culture and chemicals 
Eµ-Myc;Arf-/- mouse B-cell lymphomas were cultured in B cell medium (45% DMEM/45% 
IMDM/10% FBS, supplemented with 2 mM L-glutamine and 5µM β-mercaptoethanol). γ-
irradiated NIH 3T3 cells were used as feeder cells. Vincristine, doxorubicin, and the Rac 
inhibitor NSC23766 were purchased from Calbiochem. For in vivo studies, drugs were 
dissolved in a 0.9% NaCl solution prior to IP injection.  
 
RNAi screen 
Lymphoma cells were infected with an shRNA library targeting the cancer 1000 gene set 
(≈2250 hairpins) to a final infection of ≈20%. 48 hours after infection, lymphoma cells 
were GFP sorted. Immediately after sorting, 2x106 lymphoma cells/mouse were injected 
into three syngeneic recipient mice by tail vein injection. Disease progression was 
monitored by lymph node palpation. Following the appearance of palpable lymphomas, 
approximately 14 days after tail-vein injection, lymphoma cells were harvested from the 
axillary, brachial, and cervical lymph nodes. For in vitro samples, infected lymphoma 
cells were plated in triplicate and maintained for two weeks. shRNAs were amplified from 
genomic DNA using primers that include adaptors for 454 sequencing (Supplementary 
Table 2). Following PCR amplification of hairpins, 454 sequencing was used to identify 
constituent shRNAs in each sample. Fold change in hairpin representation after 
proliferation in vitro or in vivo was determined by comparing shRNA representation in 
each sample to that in a control cell population collected immediately after cell sorting. 
Hairpins that depleted 10-fold in all three in vitro or in vivo samples, and hairpins that 
enriched 5-fold in two out of three samples, based on a normalized read numbers, were 
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considered candidate hits. Genes were not scored as candidate hits if multiple cognate 
hairpins showed opposing effects.  All of the raw data from this screen has been 
deposited in the GEO database, accession number GSE16090. 
 
shRNA constructs 
shRNA constructs were designed and cloned as previously described (Dickins et al., 
2005). Sequences targeted by shRNAs are provided in Supplementary Table 2. 
 
Western blotting and RT-qPCR 
For western blotting and RT-qPCR, protein or total RNA was isolated after retroviral 
infection and puromycin selection. Primers used for qPCR are available upon request. 
For western blotting, cell lysates were prepared in lysis buffer (1% sodium deoxycholine, 
0.1% SDS, 1% triton-X, 10 mM Tris-HCl, pH 8.0, 140 mM NaCl) for 10 minutes. Lysates 
were cleared for 15 minutes at 14,000 rpm and mixed with 5x SDS sample buffer. 
Proteins were then run on a 12% SDS-PAGE gel, transferred to PVDF (Millipore) and 
detected with the following antibodies: anti-Rac2 (Proteintech Group, 1:200) and anti-
tubulin (ECM Biosciences, 1:5000). 
 
Competition and survival assays 
For competition assays, lymphoma cells were partially infected with the indicated 
retroviruses and 4x106 cells were tail-vein injected into syngeneic recipient mice. 
Following the appearance of palpable lymphomas, lymphoma cells were harvested from 
the lymph nodes and the percentage of GFP+ cells was analyzed on a Becton Dickinson 
FACScan flow cytometer. In parallel, lymphoma cells were maintained in culture for two 
weeks to assess the effect of the indicated shRNA on lymphoma cell proliferation in vitro. 
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Dead cells were detected by propidium iodide incorporation (0.05 mg/mL) and were 
excluded from GFP analysis. For survival assays, cells were GFP sorted and 1 x 106 
cells/mouse were injected by tail-vein injection. Mice were treated with the Rac inhibitor 
NSC23766 every 12 hours (2.5 mg/kg) starting 9 days after tail vein injection. Mice were 
treated with a single dose of vincristine (1.5 mg/kg) 11 days after tail vein injection. 
Tumor free survival was monitored by palpation and overall survival was based on body 
condition score. For short-term engraftment assays, cells were GFP or dsCherry sorted, 
mixed at an even ratio, and 1x106 cells/mouse were injected by tail-vein injection. 
 
Migration assays 
Recombinant murine SDF-1α (Peprotech) was used for migration assays. Lymphoma 
cells were serum starved in B cell media containing 2.5% FBS for 2 hours. 250,000 
lymphoma cells resuspended in low serum B cell media were added to the upper 
chamber of 24-well transwell inserts (5 µm pore size, Millipore) and the indicated 
concentration of SDF was added to the lower chamber. The number of lymphoma cells 
that migrated to the lower chamber was quantified after 5 hours and is displayed as the 
fold change in cell number relative to control wells. For live imaging of lymphoma cell 
migration, glass bottom dishes (MatTek) were coated with fibronectin (Calbiochem). 
Lymphoma cells were resusupended in low serum B cell media at 2x106 cells/mL, plated 
on fibronectin-coated dishes, and allowed to adhere for 2 hours. Non-adherent cells 
were then removed by gentle washing and cells were imaged after stimulation with SDF 
(100 ng/mL). 
 
Statistical analysis 
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Statistical analysis was performed using GraphPad Prism4 software. Two-tailed 
Student’s t-tests, one sample t-tests, and one-way ANOVA were used, as indicated. For 
comparison of survival curves, a Mantel-Haenszel test was used. Error bars represent 
standard deviation. 
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Figures 
 
 
 
Figure 1 – In vivo RNAi screening strategy. (A) A diverse population of lymphoma cells 
is retained in tumors at the time of disease presentation. Cells were infected with a 
vector control or a retrovirus co-expressing GFP and an shRNA targeting Top2A. 
Partially transduced cell populations were injected into recipient mice. Palpable tumors 
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were treated with doxorubicin, and the percentage of GFP positive lymphoma cells was 
assayed at tumor relapse. (B) In vivo RNAi screening strategy. Lymphoma cells were 
infected with a pool of retroviruses containing 2250 distinct hairpins, and transduced 
lymphoma cell populations were injected into three recipient mice or passaged in three 
separate culture dishes. Lymphomas were harvested from tumor-bearing mice and 
shRNAs were PCR amplified from genomic DNA derived from tumors or from cultured 
cells. (C) The number of unique hairpins present in each sample after two weeks 
proliferation. (D) Clustering of samples based on shRNA enrichment or depletion. Color 
scale represents the mean normalized log2 of the fold change in shRNA read number 
relative to input cells. (E) Hairpins that scored as enriched or depleted in vivo are largely 
distinct those that enriched or depleted in vitro. Diagrams show the number of scoring 
genes in the in vivo and in vitro settings.  
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Figure 2 – Functional validation of shRNAs targeting putative cell motility genes. 
(A) shRNA-mediated stable knockdown of Rac2, CrkL, and Twf1. Target protein/gene 
expression was measured by immunoblotting or qPCR. For qPCR samples, n=2 and bar 
graphs represent mean and standard deviation. (B) In vivo GFP competition assay to 
functionally validate candidate hits. Lymphoma cell cultures, partially transduced with a 
vector coexpressing GFP and the indicated shRNA, were maintained in culture for two 
weeks or injected into recipient mice.  The fold change in the percentage of GFP positive 
lymphoma cells, relative to cells at injection, is shown. p-values were determined by a 
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two-tailed Student’s t-test. (n=7 for vector control and shRac2-1, n=8 for shRac2-2 in left 
panel; n=4 for vector control, n=3 for shCrkL-1 and shCrkL-2 in middle panel; n=4 for 
vector control and shTwf-2, n=3 for shTwf-1 in right panel). (C and D) Rac2, CrkL, or 
Twf1 suppression causes chemotaxis defects in transwell migration assays. Cells 
expressing a control vector, shRac2 (C), shTwf1, or shCrkL (D) were stimulated with 
SDF-1α. The number of cells that migrated is displayed as a fold change relative to 
control wells. p-values were determined by one-way ANOVA or a two-tailed Student’s t-
test. Bar graphs represent mean and standard deviation. n=2 for each experimental 
group. 
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Figure 3 – Rac2 suppression impairs lymphoma cell migration and extends animal 
survival. (A) Rac2 suppression causes defects in short term engraftment. Lymphoma 
cells expressing dsCherry or coexpressing GFP and shRac2 were mixed, injected into 
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recipient mice, and assessed after 2 or 24 hours.  p-values were determined by one-way 
ANOVA or a one-sample t-test. Bar graphs represent mean and standard deviation. n=1 
for injected cells, n=3 for all other experimental groups. (B) Lymphoma cells suppressing 
Wave2 were depleted in an in vivo GFP competition assay. p-values were determined by 
a two-tailed Student’s t-test. (n=7 for vector control, n=4 for shWave2-1). (C) 
Suppression of Rac2 impairs lymphoma cell migration to the lymph nodes and liver. 14 
days after transplantation, shRac2 recipients show markedly reduced tumor 
dissemination. (D) Partially-transduced lymphoma cells were harvested from the liver at 
the time of disease presentation and the percentage of GFP positive cells was 
assessed. p-values were determined by one-way ANOVA. (n=7 for vector control, n=4 
for shRac2-1 and shRac2-2) (E and F) Suppression of Rac2 in lymphoma cells delays 
disease progression. GFP sorted lymphoma cells were injected into recipient mice. 
Survival is displayed in Kaplan-Meier format (n=5 mice per group for tumor free survival 
and n=10 mice per group for overall survival). 
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Figure 4 – Suppression of Rac activity delays disease progression and potentiates the 
action of the chemotherapeutic vincristine. (A) Pharmacological inhibition of Rac2 
extends animal lifespan. Mice were treated with the Rac inhibitor NSC23776 every 12 
hours starting nine days after injection of lymphoma cells. Results are shown in Kaplan-
Meier format (n=5 for each experimental group). (B) Suppression of Rac2 activity 
extends animal survival following vincristine treatment. Mice bearing vector control or 
shRac2 tumors were treated with vincristine 11 days after injection of lymphoma cells, 
and overall survival was monitored (n=11 for each experimental group. Data was 
compiled from three independent experiments).  (C) A model for the role of Rac2 in 
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relapse following vincristine treatment. The appearance of terminal disease following 
vincristine treatment may require tumor cell migration from sites of residual disease to 
metastatic sites, including liver, lung, and brain.  
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Table 1 – Genes targeted by at least 2 depleted shRNAs (on average >10-fold) in 
vivo  
 
Intended 
shRNA 
target 
Protein name Putative role in motility 
cdkn1b Cyclin-dependent 
kinase inhibitor p27 
A cell cycle independent function of p27 regulates 
cell adhesion and migration via interaction with 
RhoA. 
crkl* v-Crk sarcoma virus 
CT10 oncogene 
homolog  
An adaptor protein reported to be involved in the 
activation of Rac 
cyr61 Cysteine-rich 
angiogenic inducer 61  
A secreted protein that mediates focal adhesions 
and is involved in cell attachment and migration. 
ddx11 RAS-related C3 
botulinum substrate 2 
 
il-6* Interleukin 6  
map2k3 Map kinase kinase 3 Operates upstream of p38 MAPk to regulate cell 
adhesion. 
nek4 NIMA (never in 
mitosis gene a)-
related kinase 4  
 
opn5 Neuropsin A secreted protein that cleaves fibronectin, 
inhibiting alpha5 integrin-mediated adhesion. 
rac2* RAS-related C3 
botulinum substrate 2 
A hematopoetic-specific Rho GTPase important 
for the formation of lamellipodia during cell 
migration. 
twf1*1 Twinfilin, actin-binding 
protein, homolog 1 
(Drosophila) 
An actin monomer-binding and actin filament 
capping protein. 
yes1 v-Yes-1 Yamaguchi 
sarcoma viral 
oncogene homolog 1 
Signals downstream of CD95 to promote cell 
invasion in vivo. 
 
* - Subject to further validation  
1 – Targeted by 3 shRNAs depleted by an average of >10-fold 
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Supplementary figures 
 
 
 
Supplementary figure 1. Determination of the number of viral integrations per tumor 
cell. Single cell clones were grown from tumor samples. Hairpins were amplified from 
genomic DNA derived from single cell clones using common primers, and the resulting 
PCR product was sequenced.  A representative sequencing trace of a PCR product from 
a single cell clone is shown. 9/10 clones had one shRNA present in the PCR product, 
indicated by a single trace in the hairpin antisense sequence, and 1/10 clones contained 
two shRNAs (data not shown). 
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Supplementary Figure 2. Validation strategy. (A) A schematic representation of the 
GFP competition assay. Approximately 20-40% of the starting lymphoma cell population 
is transduced with a specific retroviral shRNA construct co-expressing GFP, and this 
partially transduced lymphoma cell population is injected into recipient mice. At the time 
of disease presentation, tumors are harvested and the percentage of GFP positive cells 
is assayed by flow cytometry. shRNAs that provide a growth advantage, disadvantage, 
or are neutral are predicted to lead to an increase, decrease, or no change in the 
percentage of GFP positive cells, respectively. (B) Lymphoma cells were partially 
transduced with the indicated shRNA and maintained in culture or injected into recipient 
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mice. Palpable tumors were harvested and the percentage of GFP positive lymphoma 
cells was assessed. The fold change in the percentage of GFP positive cells, compared 
cells at injection, is shown. p-values were determined by one-way ANOVA. (n=7 for 
vector control, n=3 for shIL-6, and n=4 for shLyn) 
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Supplementary figure 3. Validation of motility defects in cells expressing scoring 
shRNAs. (A) Suppression of candidate genes with additional shRNAs causes 
chemotaxis defects in transwell migration assays. Cells infected with the indicated 
shRNA were stimulated with SDF-1α. p-values were determined by a two-tailed  
Student’s t-test and bar graphs represent mean and standard deviation. n=2 for each 
experimental group. (B) Re-expression of Rac2 rescues chemotaxis defects in transwell 
migration assays. A mixed population of lymphoma cells was generated containing 
uninfected cells, cells infected with shRac2 co-expressing GFP, and cells infected with 
both shRac2 co-expressing GFP and an shRNA-resistant Rac2 construct co-expressing 
the fluorescent protein dsCherry. Following stimulation with SDF-1α, cells suppressing 
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Rac2 depleted in cells that had migrated, whereas, the percentage of cells expressing a 
Rac2 cDNA did not decrease. (C) shRNA-mediated stable knockdown of Wave2. 
Lymphoma cells were infected with an shRNA targeting Wave2 and target gene 
expression was measured by qPCR. Bar graphs represent mean and  
standard deviation. n=2 for all experimental groups. (D) Cells suppressing Wave2 show 
chemotaxis defects in transwell migration assays following stimulation with SDF-1α. p-
values were determined by a two-tailed Student’s t-test and bar graphs represent mean 
and standard deviation. n=2 for all experimental groups. 
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Supplementary Figure 4. Functional characterization of scoring shRNAs. (A) Inhibition 
of Rac activity impairs lymphoma cell migration in transwell migration assays. 
Lymphoma cells were pre-treated with the Rac inhibitor NSC23766 for two hours and 
were then stimulated with SDF-1α in the presence of NSC23766. p-values were 
determined by a two-tailed Student’s t-test and bar graphs represent mean and standard 
deviation. n=2 for all experimental groups. (B) Suppression of Twf1 in lymphoma cells 
extends animal lifespan. shTwf1 infected lymphoma cells were injected into recipient 
mice and survival was monitored. (n=12 for vector control, n=24 for Twf1) (C) 
Knockdown of multiple candidate genes has a synergistic effect in vivo. Pure populations 
of shTwf1 infected cells were partially transduced with an shRNA targeting Lyn, Rac2, or 
a different shRNA targeting Twf1 (all co-expressing the fluorescent protein Cherry) and 
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were injected into recipient mice. Lymphomas were harvested and the percentage of 
Cherry-positive cells was assessed. The fold change in the percentage of Cherry-
positive cells, relative to cells at injection, is shown. p-values were determined by one-
way ANOVA (n=3 for all experimental groups). (D) Suppression of Twf1 extends animal 
survival following vincristine treatment. Mice bearing shTwf1 tumors were treated with 
vincristine, and survival was monitored. (n=5 for vector control, n=4 for shTwf1). 
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Supplementary tables 
Supplementary Table 1 – Scoring shRNAs  
 
shRNAs enriched in vitro and in vivo 
 
Intended shRNA 
target Gene name 
Lima1 LIM domain and actin binding 1 
Orc4l origin recognition complex, subunit 4-like (S. cerevisiae) 
 
shRNAs enriched specifically in vitro 
 
Intended shRNA 
target Gene name 
4921537P18Rik RIKEN cDNA 4921537P18 gene 
Actb actin, beta 
Akr1b7 aldo-keto reductase family 1, member B7 
Akt2 thymoma viral proto-oncogene 2 
Apaf1 apoptotic peptidase activating factor 1 
Cd177 CD177 antigen 
Ctso cathepsin O 
Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 
Cyp2c29 cytochrome P450, family 2, subfamily c, polypeptide 29 
Dck deoxycytidine kinase 
Elk3 ELK3, member of ETS oncogene family 
Fosl2 fos-like antigen 2 
Grb7 growth factor receptor bound protein 7 
Grb8 S100 calcium binding protein A4 
Grb9 nuclear receptor coactivator 1 
Hoxb6 homeo box B6 
Hpca hippocalcin 
Klk10 kallikrein related-peptidase 10 
Klk1b26 kallikrein 1-related petidase b26 
Mcm10 minichromosome maintenance deficient 10 (S. cerevisiae) 
Mmp13 matrix metallopeptidase 13 
Nefl neurofilament, light polypeptide 
Notch4 Notch gene homolog 4 (Drosophila) 
Opn4 opsin 4 (melanopsin) 
Oxtr oxytocin receptor 
Polr2b polymerase (RNA) II (DNA directed) polypeptide B 
Prkdc protein kinase, DNA activated, catalytic polypeptide 
Rad51c RAD51 homolog c (S. cerevisiae) 
Rarb retinoic acid receptor, beta 
Rfc4 replication factor C (activator 1) 4 
Rhoa ras homolog gene family, member A 
Serpinb5 serine (or cysteine) peptidase inhibitor, clade B, member 5 
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Stx5a syntaxin 5A 
Tcf4 transcription factor 4 
Tnfrsf10b tumor necrosis factor receptor superfamily, member 10b 
Tram1 translocating chain-associating membrane protein 1 
Trp53 transformation related protein 53 
Twf1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 
Twf1 twinfilin, actin-binding protein, homolog 1 (Drosophila) 
Vwa5a* von Willebrand factor A domain containing 5A 
 
shRNAs enriched specifically in vivo 
 
Intended shRNA 
target Gene name 
4921537P18Rik RIKEN cDNA 4921537P18 gene 
Acss2 acyl-CoA synthetase short-chain family member 2 
Appbp2 amyloid beta precursor protein binding protein 2 
Arg2 arginase type II 
Bard1 BRCA1 associated RING domain 1 
Cdk6 cyclin-dependent kinase 6 
Cldn1 claudin 1 
Col1a2 collagen, type I, alpha 2 
Cpa2 carboxypeptidase A2, pancreatic 
Ddr2 discoidin domain receptor family, member 2 
F3 coagulation factor III 
Gas8 growth arrest specific 8 
Gsn gelsolin 
Hgf hepatocyte growth factor 
Igf1 insulin-like growth factor 1 
Itgav integrin alpha V 
Krit1 KRIT1, ankyrin repeat containing 
Krit1 KRIT1, ankyrin repeat containing 
Mc3r melanocortin 3 receptor 
Mcm10 minichromosome maintenance deficient 10 (S. cerevisiae) 
Mllt11 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 11 
Nme1 non-metastatic cells 1, protein (NM23A) expressed in 
Nrg2 neuregulin 2 
Olfr1350 olfactory receptor 1350 
Olfr313 olfactory receptor 313 
Pparg peroxisome proliferator activated receptor gamma 
Ppm1j protein phosphatase 1J 
Prkd3 protein kinase D3 
Prlr prolactin receptor 
Rad17 RAD17 homolog (S. pombe) 
Rarg retinoic acid receptor, gamma 
Strap serine/threonine kinase receptor associated protein 
Vegfc vascular endothelial growth factor C 
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Vwa5a* von Willebrand factor A domain containing 5A 
Wnt5a wingless-related MMTV integration site 5A 
Wwox WW domain-containing oxidoreductase 
 
* - distinct Vwa5a shRNAs scored in vitro and in vivo 
 
 
 
shRNAs depleted in vitro and in vivo 
 
Intended shRNA 
target Gene name 
Map2k6 mitogen-activated protein kinase kinase 6 
Top2a topoisomerase (DNA) II alpha 
Vdr vitamin D receptor 
 
shRNAs depleted specifically in vitro 
 
Intended shRNA 
target Gene name 
Cdkn3 cyclin-dependent kinase inhibitor 3 
Map2k3 mitogen-activated protein kinase kinase 3 
Pdcd1 programmed cell death 1 
 
shRNAs depleted specifically in vivo 
 
Intended shRNA 
target Gene name 
Abcb4 ATP-binding cassette, sub-family B (MDR/TAP), member 4 
Abcg2 ATP-binding cassette, sub-family G (WHITE), member 2 
Actr8 ARP8 actin-related protein 8 homolog (S. cerevisiae) 
Aif1∫ allograft inflammatory factor 1 
Akr1b8 aldo-keto reductase family 1, member B8 
Akt3 thymoma viral proto-oncogene 3 
Anxa1 annexin A1 
Apaf1 apoptotic peptidase activating factor 1 
Bmp10 bone morphogenetic protein 10 
Casp3 caspase 3 
Cat catalase 
Ccnd1 cyclin D1 
Ccnf cyclin F 
Col1a1 collagen, type I, alpha 1 
Crkl * v-crk sarcoma virus CT10 oncogene homolog (avian)-like 
Crkl  v-crk sarcoma virus CT10 oncogene homolog (avian)-like 
Ctsb cathepsin B 
Ctse cathepsin E 
Cyp24a1 cytochrome P450, family 24, subfam. a, polypeptide 1 
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Ddx11 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like 
helicase homolog, S. cerevisiae) 
Ddx11 
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 (CHL1-like 
helicase homolog, S. cerevisiae) 
Dnajc3 DnaJ (Hsp40) homolog, subfamily C, member 3 
Ehbp1l1 EH domain binding protein 1-like 1 
Epcam epithelial cell adhesion molecule 
Erbb4 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 
(avian) 
Ets2 E26 avian leukemia oncogene 2, 3' domain 
Fgf5 fibroblast growth factor 5 
Fgf7 fibroblast growth factor 7 
Fgfr4 fibroblast growth factor receptor 4 
Hmgb1 high mobility group box 1 
Hmmr hyaluronan mediated motility receptor (RHAMM) 
Igf1r insulin-like growth factor I receptor 
Il13 interleukin 13 
Il6 * interleukin 6 
Il6 interleukin 6 
Insr insulin receptor 
Ivns1abp influenza virus NS1A binding protein 
Krt15 keratin 15 
Lyn * Yamaguchi sarcoma viral (v-yes-1) oncogene homol. 
Map2k1 mitogen-activated protein kinase kinase 1 
Map2k4 mitogen-activated protein kinase kinase 4 
Map2k5 mitogen-activated protein kinase kinase 5 
Mmp7 matrix metallopeptidase 7 
Mx2 myxovirus (influenza virus) resistance 2 
Nek4 NIMA (never in mitosis gene a)-related expressed kinase 4 
Nr2e1 nuclear receptor subfamily 2, group E, member 1 
Olfr116 olfactory receptor 116 
Olfr295 olfactory receptor 295 
Opn5 opsin 5 
Opn5 opsin 5 
Oxtr oxytocin receptor 
Perp PERP, TP53 apoptosis effector 
Pfn1 profilin 1 
Pglyrp4 peptidoglycan recognition protein 4 
Ppp2r4 protein phosphatase 2A, regulatory subunit B (PR 53) 
Psen2 presenilin 2 
Psg17 pregnancy specific glycoprotein 17 
Rac2 * RAS-related C3 botulinum substrate 2 
Rac2 RAS-related C3 botulinum substrate 2 
Rad51 RAD51 homolog (S. cerevisiae) 
Rasa1 RAS p21 protein activator 1 
Rb1 retinoblastoma 1 
Skp2 S-phase kinase-associated protein 2 (p45) 
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Stk17b serine/threonine kinase 17b (apoptosis-inducing) 
Stx5a syntaxin 5A 
Tcf4 transcription factor 4 
Timp4 tissue inhibitor of metalloproteinase 4 
Tm4sf1 transmembrane 4 superfamily member 1 
Tpd52 tumor protein D52 
Ttc1 tetratricopeptide repeat domain 1 
Twf1 * twinfilin, actin-binding protein, homol. 1 (Drosophila) 
Tyk2 tyrosine kinase 2 
Vegfa vascular endothelial growth factor A 
Xpc xeroderma pigmentosum, complementation group C 
Yes1 Yamaguchi sarcoma viral (v-yes) oncogene homol. 1 
Yes1 Yamaguchi sarcoma viral (v-yes) oncogene homol. 1 
 
* - validated in subsequent experiments 
 
∫ - failed to validate in subsequent experiments 
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Supplementary Table 2 – Primer Sequences 
 
PCR primers used to amplify shRNAs from genomic DNA 
Primer Sequence 
Primer A 5’-GCCTCCCTCGCGCCATCAGCAGAAGGCTCGAGAAG 
GTATATTGCTGTTGACAGTGAGCG-3’ 
Primer B 5’-GCCTTGCCAGCCCGCTCAGCTAAAGTAGCCCCTTGA 
ATTCCGAGGCAGTAGGCA-3’. 
 
Sequences targeted by shRNAs 
shRNA 
construct 
Sequence targeted 
Rac2-1 5’-CCAAAGGGAGAGATGTGGAAA-3’ 
Rac2-2 5’-CAGGACCCGATCCATAGCAAA-3’ 
CrkL-1 5’-CCTGGAGTTTGCTTTATGTAA-3’ 
CrkL-2 5’-CAGGCTAAGTTCTATAGTAAA-3’ 
Twf-1 5’-CGTTACCATTTCTTTCTGTAT-3’ 
Twf-2 5’-GCAGTTGGAAATAGATATAAA-3’ 
 
Additional shRNA sequences are available upon request. 
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Abstract 
 
 RNAi screening approaches have been extensively used in vitro to identify novel 
genes that impact tumor cell biology. However, these approaches have not been broadly 
adapted to in vivo systems. Here, we have used a transplantable model of B-cell acute 
lymphoblastic leukemia to perform a genome-scale shRNA screen for modulators of 
tumor progression in vivo. We have identified a large set of genes that uniquely impact 
leukemia cell growth in the in vivo setting, including a number of established leukemia 
genes, like Runx, Lmo2, and Phf6. While inactivating mutations in Phf6 are commonly 
observed in human T-cell acute lymphoblastic leukemia, we have found that suppression 
of this gene in B-cell malignancies impairs tumor progression, suggesting that Phf6 may 
play a lineage-specific role in hematopoietic malignancies.  
 
Introduction 
 Retroviral insertional mutagenesis screens (Lund et al., 2002; Mikkers et al., 
2002; Suzuki et al., 2002) and transposon-based screens (Collier et al., 2005; Dupuy et 
al., 2005) have been used as a tool for genetic discovery in hematopoietic and solid 
tumors. These screens have identified a number of novel genes that drive tumor 
initiation and progression, but are biased towards the identification of gain-of-function 
mutations and are primarily limited to positive selection screens. Using RNAi based 
screening approaches, it is possible to examine loss of function phenotypes in 
mammalian cells (Berns et al., 2004; Ngo et al., 2006; Paddison et al., 2004; Schlabach 
et al., 2008; Silva et al., 2008). These screens have been effective in identifying genes 
necessary for the proliferation and survival of transformed cells, but they have primarily 
	   80	  
been limited to in vitro systems. Recently, we, and others, have adapted pool-based 
shRNA screening approaches to in vivo applications in transplantable tumors. Low-
complexity shRNA pools were used to screen for tumor suppressors in mouse models of 
liver cancer (Zender et al., 2008) and B-cell lymphoma (Bric et al., 2009). Using a 
moderately-sized shRNA library, we performed an in vivo screen for genes that impacted 
disease progression in established B-cell lymphomas, and were able to introduce nearly 
1000 genetic lesions into individual animals (Meacham et al., 2009). A similar number of 
genetic alterations were also introduced into a transplantable model of acute myeloid 
leukemia using an inducible shRNA system (Zuber et al., 2011). 
 Thus far, no genome-scale shRNA screens have been performed in vivo. Here, 
we report the first example of such a screen. We have used five pools of 10,000 hairpins 
each to screen for genes that impact leukemia growth in a transplantable model of B-cell 
acute lymphoblastic leukemia. Importantly, in this model, we can identify as many as 
9,000 unique shRNAs in the tumor burden from individual animals, and thus, are able to 
simultaneously assay the effect of thousands of genetic alterations in vivo. We 
performed a parallel screen in vitro, and found that many shRNAs uniquely impacted 
leukemia cell proliferation in the in vitro or in vivo settings. This approach has allowed us 
to identify genetic dependencies that are unique to tumor cells growing in the in vivo 
context. 
 
Results and Discussion 
 Here, we have utilized a transplantable model of B-cell acute lymphoblastic 
leukemia (ALL) to perform a genome-scale screen for modulators of disease progression 
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in vivo. Specifically, in this model, transplantation of Arf-/- pre-B cells that express the 
p185 Bcr-Abl fusion protein into syngeneic recipient mice produces a B-cell leukemia 
within approximately two weeks (Williams et al., 2007; Williams et al., 2006). Importantly, 
since leukemias are transplanted into syngeneic mice, tumor cell growth occurs within 
the context of normal microenvironmental cues of the hematopoietic system. In this 
model, transplantation of as few as 20 leukemia cells is sufficient to produce disease in 
100% of recipient animals (Williams et al., 2007). This, along with the relatively short 
latency in which disease arises, suggests that large numbers of leukemia cells are 
contributing to disease following transplantation. Therefore, we reasoned that this model 
might accommodate the introduction of diverse shRNA sets into transplanted tumors. 
Initially, to assess our ability to maintain library diversity in vivo, we introduced a 
moderately-sized shRNA library into transplanted tumor cells. Specifically, leukemia cells 
were transduced ex vivo with a pooled shRNA library containing approximately 2200 
shRNAs that co-express the fluorescent protein GFP. We then sorted shRNA infected 
cells, and injected this cell population into recipient animals. At the time of terminal 
disease, tumor cells were harvested from the blood of mice, shRNAs were PCR 
amplified from tumors, and high throughput sequencing was used to assess hairpin 
representation. We could identify between 1800 and 1900 unique shRNAs in tumor cells 
derived from individual mice, suggesting that, starting with this library of 2200 shRNAs, 
the majority of library complexity was maintained in the in vivo setting (Supplementary 
figure 1). 
 In previous work, we have found that we could represent, at most, 900 unique 
hairpins in vivo in a transplantable lymphoma model (Meacham et al., 2009), likely due 
to limited numbers of cells seeding disease in this system. Here, the identification of 
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1900 unique shRNAs in a single mouse indicates that large numbers of transplanted 
cells are contributing to tumor burden, and, therefore, that very large shRNA sets could 
potentially be introduced in vivo. Based on this finding, we decided to use a genome-
scale shRNA library, composed of five pools containing approximately 10,000 shRNAs 
each, to screen for modulators of leukemia growth in the in vivo setting. Leukemia cells 
were transduced with single pools of 10,000 shRNAs, and infected cells were injected 
into recipient mice or, in parallel, placed in culture (Figure 1a). Growth in both contexts 
allowed us to compare shRNAs that impact leukemia cell proliferation in vitro and in vivo. 
Once overt disease developed, leukemia cells were harvested from the blood of recipient 
animals and from cultured samples, shRNAs were PCR amplified from genomic DNA, 
and shRNA pool composition was deconvoluted using high-throughput sequencing. With 
injected cell populations containing 10,000 distinct shRNAs, we could detect, on 
average, between 7000 and 8000 unique hairpins in tumors derived from individual mice 
(Figure 1b). Unlike previous pool-based in vivo shRNA screens, where the number of 
unique hairpins represented in tumors has been limited to hundreds of shRNAs, in this 
model, thousands of shRNAs can be represented in vivo. In some mice, only 5000 to 
6000 unique shRNAs could be identified, either due to smaller numbers of cells seeding 
disease in those tumors, or due to the clonal outgrowth of subsets of tumor cells, which 
can reduce the representation of other shRNA infected leukemia cells. However, even in 
these mice, we are still able to represent significantly more hairpins than has been 
reported in other in vivo screens. To assess the upper limit of the number of hairpins that 
can be detected in individual tumors, we also combined all five pools of shRNAs and 
introduced this set of 50,000 hairpins into tumor cells prior to transplantation, and found 
that we could identify as many as 30,000 unique shRNAs in tumors from individual 
animals at the time of terminal disease (Supplementary figure 1). Thus, in this model of 
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B-cell ALL, we can systematically examine the impact of the loss of function of tens of 
thousands of genes on tumor cell growth in vivo using large, unbiased shRNA libraries. 
 When samples were clustered based on the enrichment and depletion of shRNAs 
within each sample, the in vivo samples clustered together, as did the in vitro samples, 
suggesting that differential selective pressure causes hairpins to behave in distinct ways 
in these two settings, and that this behavior is sufficient to distinguish in vitro samples 
from in vivo samples. (Figure 1c). Additionally, the behavior of hairpins in vitro is poorly 
correlated with the behavior of hairpins in vivo (Figure 1d and 2a), and the set of 
shRNAs that deplete, on average, at least four-fold in the in vivo setting is largely non-
overlapping with the set of shRNAs that depleted to the same extent in vitro (Figure 2b). 
Together, these results indicate that shRNA-mediated suppression of target genes may 
differentially impact tumor cell growth in vitro and in vivo and suggest that leukemia cells 
may have unique genetic dependencies in the in vivo setting, due to factors like altered 
requirements for growth and survival in the presence of local microenvironmental cues. 
Thus, performing screens in vivo may allow context-specific determinants of disease 
progression to be identified. 
 For validation studies, we focused on shRNAs that depleted specifically in the in 
vivo setting. Hairpins that depleted an average of four-fold in vivo and did not deplete 
more that 25% in vitro were considered candidates for validation. The set of scoring 
shRNAs by these criteria contained approximately 1700 hairpins that target annotated 
genes, predicted genes, and predicted proteins. Functional categorization of the genes 
targeted by scoring shRNAs (Huang da et al., 2009a, b) based on structural features 
revealed that these genes were enriched for a number of common protein domains 
(Figure 2c). These domains included C2H2 type zinc finger protein domains, which 
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primarily regulate gene expression (Iuchi, 2001), Kelch and BTB/POZ domains, which 
are involved in protein-protein interactions and regulate diverse cellular processes 
(Collins et al., 2001), and plant homeodomain (PHD) fingers, which recognize specific 
histone modifications and are part of multimeric complexes that can activate or repress 
gene transcription (Musselman and Kutateladze, 2011; Sanchez and Zhou, 2011). To 
validate candidate hairpins, we made use of in vitro and in vivo GFP competition assays, 
where leukemia cells were partially transduced with individual shRNA constructs 
coexpressing GFP, and were then injected into recipient mice or placed in culture. To 
assess the impact of a given hairpin on tumor cell growth, leukemia cells were harvested 
after a period of in vitro or in vivo proliferation, and the percentage of GFP positive cells 
was assayed by FACs (Figure 2d). In total, out of the eighteen shRNAs tested targeting 
genes containing Kelch and C2H2 zinc finger domains, eight depleted in vivo as single 
constructs (Figure 2e), suggesting a high validation rate for this dataset. Importantly, 
these shRNAs differentially impacted leukemia cell growth in vivo and in vitro; whereas 
these hairpins were neutral or, in some instances, provided a growth advantage in the in 
vitro context, they depleted in tumor cells harvested from mice. By performing screens in 
vivo, we have identified a number of shRNAs that negatively impact tumor cell 
proliferation specifically in the in vivo setting. 
 As another filter to select candidate shRNAs for validation, we also generated 
transcriptional data from leukemia cells that were growing in vitro and in vivo.  Like the 
screening data, these transcriptional profiles were sufficient to distinguish in vitro 
samples from in vivo samples using unsupervised clustering approaches (Figure 3a), 
and a large number of genes were significantly differentially expressed between the two 
settings. To identify genes that might be functionally important in the in vivo setting, we 
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compared the genes that were transcriptionally upregulated in vivo to those that were 
targeted by hairpins that depleted specifically in vivo, which revealed that the overlap 
between these gene sets was limited (Figure 3b and Supplementary table 1). Before 
individually testing candidate hairpins targeting this overlapping gene set, we built a 
small, high coverage validation library that contained six independent shRNAs directed 
at each of the 133 genes in this set. As a rapid and cost effective method of generating a 
validation library, shRNA oligonucelotides were synthesized on a chip, eluted, PCR 
amplified and bulk cloned into our shRNA expression vector. This bulk-cloned library 
was directly used to re-screen for modulators of leukemia cell growth in vitro and in vivo 
(Figure 3c). Only genes that had at least two independent shRNAs deplete specifically in 
vivo in this secondary screen (Supplementary table 2) were considered candidates for 
individual validation studies.  
 When candidate hairpins were validated as individual constructs, five shRNAs 
depleted both in vitro and in vivo (Figure 3d), eight shRNAs depleted specifically in the in 
vivo setting, including two shRNAs targeting the C2H2 zinc finger proteins PogZ and 
Zfp28 (Figure 2e and 3e), and two shRNAs failed to validate. Two of the shRNAs that 
depleted specifically in the in vivo setting targeted Lmo2 and Runx1, genes with 
established roles in hematopoietic malignancies. Lmo2 translocations, resulting in 
overexpression of the full length Lmo2 protein, are found in T cell malignancies and have 
been suggested, at least in part, to promote tumorigenesis by blocking T cell 
development (Curtis and McCormack, 2010; McCormack et al., 2010). Thus far, a role 
for Lmo2 in B cell malignancies has not been well established. Runx translocations have 
been identified in B cell and myeloid malignancies. Whereas translocations result in the 
truncation of Runx in myeloid malignancies, full-length Runx is expressed in B-cell 
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malignancies (Golub et al., 1995; Romana et al., 1995), and it is unclear if Runx plays an 
oncogenic or tumor suppressor role in B-cell diseases.  Supporting an oncogenic role for 
Runx, activating Runx mutations have been identified in insertional mutagenesis screens 
in B and T cell malignancies (Stewart et al., 1997; Wotton et al., 2002) and Runx gene 
overexpression has been observed in human B-cell ALL (Niini et al., 2002). In our 
datasets, both Runx and Lmo2 are transcriptionally upregulated in the in vivo setting, 
and hairpins targeting these genes confer a growth disadvantage, which indicates that 
Runx and Lmo2 are functionally important in vivo and that they may play a pro-
oncogenic role in B cell malignancies. However, neither of these genes are involved in 
signaling downstream of Bcr-Abl, suggesting that leukemia cells may be utilizing 
alternative oncogenic pathways involving of Runx and Lmo2 for growth or survival in 
vivo. 
 As a final means of filtering our shRNA screening data using existing biological 
datasets, we compared genes targeted by shRNAs that depleted in vivo with genes 
contained within amplicons found in human ALL patients (Beroukhim et al., 2010; Kuiper 
et al., 2007; Mullighan et al., 2008), which may facilitate the identification of genes that 
are functionally important within these large regions of amplification, as well as genes 
whose suppression has more pronounced phenotypic consequences. We mapped the 
genomic locations of the human orthologs of genes targeted by scoring shRNAs, and 
looked for genes that fell within amplified regions. A number of shRNAs targeting genes 
contained within ALL amplicons validated as single constructs (Figure 4a), including 
hairpins targeting the plant homeodomain finger protein, Phf6. Inactivating Phf6 
mutations are frequently found in T-cell acute lymphoblastic leukemia (Zuber et al., 
2009), and less frequently, acute myeloid leukemia (Van Vlierberghe et al., 2011), but 
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mutations have not been detected in B-lineage malignancies (Zuber et al., 2009). In 
contrast to T cell and myeloid malignancies, where inactivation of Phf6 promotes tumor 
development, our data suggests that suppression of Phf6 in B-cell leukemias may 
negatively impact disease progression, specifically in the in vivo setting. In all 
hematopoietic organs tested, including the spleen and bone marrow, where the majority 
of tumor cell proliferation occurs, the suppression of Phf6 was selected against, and in 
GFP competition assays, the percentage of cells suppressing Phf6 decreased 
progressively after transplantation, indicative of a role for this gene in leukemia cell 
growth or survival in vivo, rather than engraftment following transplantation. Suppression 
of Phf6 in pure populations of transplanted leukemia cells also significantly reduced 
peripheral leukemia burden in recipient animals, relative to a vector control (Figure 4B).  
 In a transplantable model of Burkitt’s lymphoma, another B-cell malignancy, 
suppression of Phf6 was also specifically selected against in the in vivo context (Figure 
4c), indicating the Phf6 suppression negatively impacts tumor growth in   multiple B-cell 
diseases. When we looked at the effect of this hairpin in a transplantable T cell 
lymphoma, we found that hairpin-mediated suppression of Phf6 was neutral (Figure 4e), 
suggesting differential requirements for Phf6 gene function in B and T cell lineages. 
Additionally, cDNA-mediated Phf6 overexpression was potently selected against in T cell 
lymphomas (Figure 4e), whereas it was neutral in B-cell ALLs in vivo (Figure 4d). 
Together, these results indicate that Phf6 may play a lineage-specific role in 
hematopoietic malignancies, where overexpression of Phf6 impairs tumor cell growth in 
T cell malignancies, and suppression of Phf6 hinders disease progression in B cell 
malignancies. Importantly, these effects were observed only in the in vivo context, 
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suggesting that the in vivo tumor microenvironment influences the genetic dependencies 
of tumor cells. 
 Here, in a transplantable model of B-cell acute lymphoblastic leukemia, we have 
reported the first example of a large-scale unbiased shRNA screen in vivo. This system 
permits the introduction of thousands of shRNAs into individual animals, allowing for the 
simultaneous assessment of the impact of loss-of-function events in tumors. By 
performing parallel screens in vitro and in vivo, we were able to compare the set of 
shRNAs that impacted tumor cell growth in these two settings, and identified a set of 
hairpins that uniquely influenced tumor cell growth in vivo. To select shRNAs for 
validation, genes targeted by this set of hairpins were functionally categorized, and were 
also filtered using transcriptional datasets and human copy number alteration datasets. 
The suppression of a number of genes impaired leukemia cell growth only in the in vivo 
setting in validation studies, suggesting that differential selective pressures in vivo and in 
vitro influence the genetic dependencies of tumor cells.  
 We also found that a number of established leukemia genes had unexpected 
roles in leukemia cell proliferation in vivo. In this Bcr-Abl B-ALL model, the suppression 
of Runx and Lmo2 impaired disease progression, suggesting that Bcr-Abl driven B-cell 
leukemias may rely on growth and survival signals downstream of these genes. In other 
malignancies, these genes are activated by translocation events, and they act as the 
driving oncogenic lesion in tumors. Here, dependence on these genes occurs in the 
context of enforced expression of the oncogenic Bcr-Abl fusion protein, indicating that 
Bcr-Abl driven leukemia cells engage alternative oncogenic pathways in the in vivo 
setting. Suppression of the plant homeodomain protein Phf6 also impaired leukemia cell 
growth in vivo in B cell tumors; in contrast, human mutational data indicates that Phf6 
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loss is a key event in tumor progression in a subset of T-cell ALLs. Thus, Phf6 may 
differentially impact hematopoietic malignancies in a lineage-specific manner. 
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Materials and Methods 
Cell culture 
Bcr-Abl  mouse acute lymphoblastic leukemia cells were cultured in RPMI 
(supplemented with 10% FBS,  4 mM L-glutamine and 5µM β-mercaptoethanol)  
RNAi screen 
To preserve library complexity, a minimum of 200-fold coverage of shRNA libraries was 
maintained at all steps in the screen. Leukemia cells were infected with individual pools 
of 10,000 shRNAs each to a final infection percent of 5-10%. 48 hours after infection, 
lymphoma cells were GFP sorted. 24-48 hours after sorting, 2x106 leukemia cells/mouse 
were injected into three syngeneic recipient mice by tail vein injection. At the time of 
injection, 4 million cells were collected to serve as the input sample. Disease progression 
was monitored by peripheral blood counts. Following the appearance of overt leukemias, 
approximately 12 days after tail-vein injection, leukemia cells were harvested from the 
blood of mice. For in vitro samples, infected leukemia cells were plated in triplicate and 
maintained for two weeks. Genomic DNA was isolated by proteinase K digestion and 
isopropanol precipitation. The antisense strand of shRNAs was amplified from genomic 
DNA using primers that include 1 basepair mutations to barcode individual samples 
(unmutated primers 5’ loop primer; NNNNNTAGTGAAGCCACAGATGTA; unmutated 3’ 
primer NNNNTTGAATTCCGAGGCAGTAGG). All PCR steps were performed in a UV 
hood to avoid cross-contamination between samples. Hairpins were amplified in multiple 
50 uL reactions using HotStar Taq (Qiagen). After PCR amplification, samples were 
pooled and prepared for sequencing with Illumina’s genomic adaptor kit. At least 41 
bases of the PCR product were sequenced with an Illumina HiSeq 2000 machine. 
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shRNAs with less than 100 reads in the input sample were excluded from further 
analysis, and read numbers for each shRNA were normalized to the total read numbers 
per sample to allow for cross-comparison between samples.  
Validation assays 
For GFP competition assays, pure populations of mCherry positive ALL cells were 
partially transduced with single shRNA constructs co-expressing GFP, and were infected 
to a final percentage of 40-60% GFP positive cells. 1x10^6 cells were injected into 6wk 
C57/BL6 females, and at the time of terminal disease, determined by body condition 
score, leukemia cells were harvested from the blood of mice. The percentage of GFP+ 
cells was analyzed on a Becton Dickinson LSRII.  
Microarray analysis 
Microarray studies were performed using Affymetrix Mouse Genome 430 2.0 arrays 
Validation library cloning  
shRNAs oligos were designed using siScales 
(http://gesteland.genetics.utah.edu/siRNA_scales/) and were bulk synthesized by LC 
Sciences (LC Sciences OligoMix). Eluted oligos were PCR amplified using the following 
primers:  
XhoI 5' primer; 5' CAGAAGGCTCGAGAAGGTATATTGCTGTTGACAGTGAGCG   3' 
EcoRI 3' primer; 5' CTAAAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA  3' 
and were batch cloned into a mir30 retroviral vector (Dickins et al., 2005). 
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Figure 1 Genome-scale in vivo RNAi screening in a transplantable model of acute 
lymphoblastic leukemia (A) In vivo RNAi screening strategy. Leukemia cells were 
transduced with pooled retroviral shRNA libraries containing 10,000 distinct shRNAs co-
expressing GFP. Following infection, cells were sorted for GFP, and injected into 
recipient mice or maintained in culture. Leukemia cells were harvested from tumor-
bearing animals, hairpins were amplified from genomic DNA, and shRNA representation 
was deconvoluted using high throughput sequencing. (B) shRNA library complexity is 
maintained in the in vivo setting. The number of unique hairpins detected in each sample 
is shown (C) Clustering of samples based on the enrichment or depletion of shRNAs. 
Data is displayed as the log2 of the fold change for each shRNA, and the fold change 
has been normalized the median fold change across all shRNAs in a sample. For this 
analysis, leukemia cells were transduced with the combined set of 50,000 shRNAs prior 
to screening, and hairpins with less than 100 reads in the input sample were excluded 
(D) Scatterplot showing the correlation between the average behavior of hairpins in vitro 
and in vivo for leukemia cells transduced with the combined set of 50,000 shRNAs. r-
value represents a Spearman correlation coefficient. 
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Figure 2 Characterization of shRNAs that deplete in vivo. (A) Abundance of shRNAs in 
tumors harvested from mice or cells maintained in culture. Data is displayed as the 
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average of the log2 fold change of in vivo (red) or in vitro (blue) samples relative to the 
input population. shRNAs are rank ordered based on the average fold change in vivo 
(left) or in vitro (right). Data is combined from five screens using individual pools of 
10,000 shRNAs in each screen. (B) Unique sets of hairpins score as depleted in vivo 
and in vitro. Venn diagrams show the number of shRNAs that were four-fold depleted, on 
average, in vitro and in vivo. The fold change for each shRNA was normalized to the 
median fold change across all shRNAs in the in vivo or in vitro settings. (C) shRNAs that 
deplete in vivo are enriched for a number of common protein domains. shRNAs that 
depleted an average of 4-fold in vivo and less than 25% in vitro were functionally 
categorized using the DAVID functional annotation program (D) Validation strategy for 
individual shRNAs. Cells were partially transduced with single shRNA constructs co-
expressing GFP, and injected into mice or placed in culture. After a period of in vitro or in 
vivo proliferation (approximately two weeks) the percentage of GFP positive cells was 
quantified by FACs. (E) Suppression of genes containing Kelch and C2H2 zinc finger 
protein domains is selected against in vivo. Results from in vitro and in vivo GFP 
competition assays are displayed as the fold change in the percentage of GFP positive 
cells relative to an input cell population. p-values were calculated using a two-tailed 
student’s T-test. 
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Figure 3 Validation of hairpins targeting genes that are transcriptionally altered in 
leukemia cells in vivo. (A) Clustering of tumor cells harvested from leukemic mice or 
culture based on their transcriptional profiles. (B) Overlap between genes that are 
induced in vivo and genes targeted by shRNAs that deplete in our screening data. (C) 
Secondary screening strategy. Six hairpins targeting all genes that overlapped between 
microarray and screening datasets were bulk synthesized and cloned into a retroviral 
expression vector, and this high-coverage library was used to re-screen for genes that 
depleted in vivo and were targeted by multiple independent hairpins (D) Suppression of 
established leukemia genes impairs B-ALL growth in vivo. shRNAs targeting genes that 
scored as depleted in the secondary screen were validated as single constructs in GFP 
competition assays. Results are displayed as the fold change in the percentage of GFP 
positive cells relative to an input population for shRNAs that depleted in the in vitro and 
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in vivo settings (left panel) or hairpins that depleted specifically in vivo (center and right 
panel). Hairpins targeting Runx and Lmo2 depleted specifically in vivo 
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Figure 4 Characterization of Phf6 suppression in vivo in B and T cell malignancies. (A) 
Validation of shRNAs that target genes found in regions of amplification of human ALL 
patients. (B) Characterization of Phf6 suppression in ALL cells. An shRNA targeting Phf6 
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selectively depletes in vivo in the blood, spleen, and bone marrow in a GFP competition 
assay (left panel), and the percentage of cells suppressing Phf6 progressively decreases 
over time following tail vein injection (center panel). Suppression of Phf6 in pure 
populations of leukemia cells decreases peripheral leukemia burden (right panel). (C) 
Suppression of Phf6 is selected against in vivo in transplanted Eµ-myc tumors. Two 
independent primary lymphomas were used in this experiment. (D) Phf6 overexpression 
does not impact B-cell ALL growth in vivo. Leukemia cells were partially transduced with 
the mouse Phf6 cDNA co-expressing GFP and injected into recipient mice in a GFP 
competition assay. Results are displayed as the fold change in the percentage of GFP 
positive cells relative to the input population. (E) Phf6 suppression differentially impacts 
B and T cell malignancies. A GFP competition assays shows the effect of Phf6 
suppression and overexpression in transplanted T cell lymphomas. 
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Supplementary Figure 
 
Supplementary Figure 1 Library complexity is maintained in transplanted tumors in a 
mouse model of Bcr-Abl acute lymphoblastic leukemia (A) Screening strategy to identify 
the number of unique shRNAs that can be represented in vivo. Leukemia cells were 
infected with a pool of 2200 shRNAs coexpressing GFP, sorted for GFP, and injected 
into mice. At the time of terminal disease, leukemia cells were harvested and hairpin 
representation was assessed by high throughput sequencing. (B) Number of unique 
shRNAs identified in the tumor burden from individual mice when a library of 2200 
shRNAs was introduced into leukemia cells prior to transplantation. (C) Number of 
unique shRNAs identified in individual mice when a library of 50,000 shRNAs was 
introduced into leukemia cells prior to transplantation. A minimum of 10 reads was 
required for an shRNA to be included in the unique shRNA count. 
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Supplementary tables – Supplementary table 1 
Supplementary table 1 
Overlapping set of genes from transcriptional data and screening data. Genes that were 
significantly transcriptionally upregulated in leukemia cells harvested from the blood of mice relative 
to leukemia cells maintained in culture, and genes that were targeted by hairpins that depleted at 
least four-fold in vivo and less than 25% in vitro. 
Adam19 a disintegrin and metallopeptidase domain 19  
Abhd1 abhydrolase domain containing 1  
Acox3 acyl-Coenzyme A oxidase 3, pristanoyl 
Arf2 ADP-ribosylation factor 2  
Aff1 AF4/FMR2 family, member 1 
Arrb1 arrestin, beta 1 
Atg2a ATG2 autophagy related 2 homolog A (S. cerevisiae) 
Atp13a2 ATPase type 13A2 
Atp7a ATPase, Cu++ transporting, alpha polypeptide 
Btg1 B-cell translocation gene 1, anti-proliferative 
Bbs4 Bardet-Biedl syndrome 4 (human)  
Baz2b bromodomain adjacent to zinc finger domain, 2B 
Cabin1 calcineurin binding protein 1 
Cabin1 calcineurin binding protein 1 
Cask calcium/calmodulin-dependent serine protein kinase (MAGUK family) 
Ctsc cathepsin C 
Cd177 CD177 antigen 
BC006779 cDNA sequence BC006779 
Ccrl1 chemokine (C-C motif) receptor-like 1 
Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle) 
Chd8 chromodomain helicase DNA binding protein 8  
Cobll1 Cobl-like 1 
Ccdc84 coiled-coil domain containing 84 
Ctdsp2 
CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small 
phosphatase 2 
BC035295 cysteine-serine-rich nuclear protein 2 
Cyth2 cytohesin 2 
Dcaf8 DDB1 and CUL4 associated factor 8 
Diablo diablo homolog (Drosophila) 
Dvl1 dishevelled, dsh homolog 1 (Drosophila)  
Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9 
Emr4 EGF-like module containing, mucin-like, hormone receptor-like sequence 4 
Efna1 ephrin A1 
Fam160a2 family with sequence similarity 160, member A2 
Fam193a family with sequence similarity 193, member A 
Glb1l galactosidase, beta 1-like 
Gpcpd1 glycerophosphocholine phosphodiesterase GDE1 homolog (S. cerevisiae) 
Gvin1 GTPase, very large interferon inducible 1 
H2afj H2A histone family, member J 
Hspa1b heat shock protein 1B 
Herc3 hect domain and RLD 3 
Hps5 Hermansky-Pudlak syndrome 5 homolog (human) 
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Hmha1 histocompatibility (minor) HA-1 
Ikbip IKBKB interacting protein 
Itpkb inositol 1,4,5-trisphosphate 3-kinase B 
Itm2b integral membrane protein 2B 
Klhl17 kelch-like 17 (Drosophila) 
Klhl6 kelch-like 6 (Drosophila)  
L3mbtl3 l(3)mbt-like 3 (Drosophila) 
Lrrn3 leucine rich repeat protein 3, neuronal 
Lif leukemia inhibitory factor 
Lnx2 ligand of numb-protein X 2  
Lmo2 LIM domain only 2 
Mmp9 matrix metallopeptidase 9 
Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 
Morc3 microrchidia 3 
Mgst1 microsomal glutathione S-transferase 1 
Myh9 myosin, heavy polypeptide 9, non-muscle  
Myh9 myosin, heavy polypeptide 9, non-muscle  
Nfe2l1 nuclear factor, erythroid derived 2,-like 1 
Nfe2l1 nuclear factor, erythroid derived 2,-like 1 
Ostm1 osteopetrosis associated transmembrane protein 1  
Pdrg1 p53 and DNA damage regulated 1 
Pon2 paraoxonase 2 
Pdzd2 PDZ domain containing 2 
Pex1 peroxisomal biogenesis factor 1 
Phactr2 phosphatase and actin regulator 2 
Ppap2a phosphatidic acid phosphatase type 2A 
Pik3r3 phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) 
Plac8 placenta-specific 8 
Pafah1b3 platelet-activating factor acetylhydrolase, isoform 1b, subunit 3 
Plekhn1 pleckstrin homology domain containing, family N member 1 
Pogz pogo transposable element with ZNF domain 
Parp6 poly (ADP-ribose) polymerase family, member 6 
Pan2 polyA specific ribonuclease subunit homolog (S. cerevisiae) 
Prkar2b protein kinase, cAMP dependent regulatory, type II beta 
Ptprs protein tyrosine phosphatase, receptor type, S 
Plp2 proteolipid protein 2 
Rab2b RAB2B, member RAS oncogene family 
Trp53inp2 ransformation related protein 53 inducible nuclear protein 2 
Rin3 Ras and Rab interactor 3 
Rassf5 Ras association (RalGDS/AF-6) domain family member 5 
Rasal3 RAS protein activator like 3  
Rragc Ras-related GTP binding C 
Reep2 receptor accessory protein 2 
Arhgap25 Rho GTPase activating protein 25  
Arhgap26 Rho GTPase activating protein 26 
1100001G20Rik RIKEN cDNA 1100001G20 gene 
1700020O03Rik RIKEN cDNA 1700020O03 gene 
1700109H08Rik RIKEN cDNA 1700109H08 gene 
2610008E11Rik RIKEN cDNA 2610008E11 gene 
2700081O15Rik RIKEN cDNA 2700081O15 gene 
4930470P17Rik RIKEN cDNA 4930470P17 gene 
4931406C07Rik RIKEN cDNA 4931406C07 gene 
4933437N03Rik RIKEN cDNA 4933437N03 gene 
5133401N09Rik RIKEN cDNA 5133401N09 gene 
5730508B09Rik RIKEN cDNA 5730508B09 gene 
9130008F23Rik RIKEN cDNA 9130008F23 gene 
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A630001G21Rik RIKEN cDNA A630001G21 gene 
E130309D02Rik RIKEN cDNA E130309D02 gene 
Rnf114 ring finger protein 114 
Robo3 roundabout homolog 3 (Drosophila) 
Runx1 runt related transcription factor 1 
Sesn3 sestrin 3 
Sik3 SIK family kinase 3 
Ssbp2 single-stranded DNA binding protein 2 
Sirt5 sirtuin 5  
Smg1 SMG1 homolog, phosphatidylinositol 3-kinase-related kinase (C. elegans) 
Slc39a1 solute carrier family 39 (zinc transporter), member 1 
Slc9a9 solute carrier family 9 (sodium/hydrogen exchanger), member 9 
Spnb2 spectrin beta 2 
Tagap T-cell activation Rho GTPase-activating protein 
Tnks2 tankyrase, TRF1-interacting ankyrin-related ADP-ribose polymerase 2 
Sin3a transcriptional regulator, SIN3A (yeast)  
Tgm2 transglutaminase 2, C polypeptide 
Timm8a2 translocase of inner mitochondrial membrane 8 homolog a2 (yeast) 
Tmcc2 transmembrane and coiled-coil domains 2 
Tsc22d3 TSC22 domain family, member 3 
Ube2h ubiquitin-conjugating enzyme E2H 
Unkl unkempt-like (Drosophila) 
Usp6nl USP6 N-terminal like 
Mycn v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian) 
Vamp5 vesicle-associated membrane protein 5 
Wdr24 WD repeat domain 24 
Wdr26 WD repeat domain 26 
Ythdf2 YTH domain family 2 
Zbtb4 zinc finger and BTB domain containing 4 
Zbtb48 zinc finger and BTB domain containing 48 
Zfp161 zinc finger protein 161  
Zfp28 zinc finger protein 2 
Zfp263 zinc finger protein 263 
Zfp408 zinc finger protein 408 
Zfp598 zinc finger protein 598 
Zfyve9 zinc finger, FYVE domain containing 9 	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Supplementary tables – Supplementary table 2 
Supplementary table 2 
Genes from the microarray overlap validation screen that were targeted by two or more depleting 
shRNAs. The average fold change for each shRNA in vivo (relative to the input cell population) was 
divided by the average fold change of that shRNA in vitro to identify hairpins that specifically depleted 
in vivo. shRNAs were rank ordered based on this value, and the bottom 30% of shRNAs were 
considered depleting shRNAs 
Number of 
independent 
shRNAs Gene symbol Gene name 
4 Chd8 chromodomain helicase DNA binding protein 8  
4 Klhl17 kelch-like 17 (Drosophila) 
4 Lmo2 LIM domain only 2 
      
3 1700020O03Rik RIKEN cDNA 1700020O03 gene 
3 1700109H08Rik RIKEN cDNA 1700109H08 gene 
3 2700081O15Rik RIKEN cDNA 2700081O15 gene 
3 4931406C07Rik RIKEN cDNA 4931406C07 gene 
3 Acox3 acyl-Coenzyme A oxidase 3, pristanoyl 
3 Adam19 a disintegrin and metallopeptidase domain 19  
3 Arf2 ADP-ribosylation factor 2  
3 Baz2b bromodomain adjacent to zinc finger domain, 2B 
3 Ctsc cathepsin C 
3 Dcaf8 DDB1 and CUL4 associated factor 8 
3 Dvl1 dishevelled, dsh homolog 1 (Drosophila)  
3 E130309D02Rik RIKEN cDNA E130309D02 gene 
3 Herc3 hect domain and RLD 3 
3 Hmha1 histocompatibility (minor) HA-1 
3 L3mbtl3 l(3)mbt-like 3 (Drosophila) 
3 Lnx2 ligand of numb-protein X 2  
3 Lrrn3 leucine rich repeat protein 3, neuronal 
3 Ms4a6c 
membrane-spanning 4-domains, subfamily A, member 
6C 
3 Myh9 myosin, heavy polypeptide 9, non-muscle  
3 Pdzd2 PDZ domain containing 2 
3 Plekhn1 
pleckstrin homology domain containing, family N 
member 1 
3 Reep2 receptor accessory protein 2 
3 Rragc Ras-related GTP binding C 
3 Smg1 
SMG1 homolog, phosphatidylinositol 3-kinase-related 
kinase (C. elegans) 
3 Tagap T-cell activation Rho GTPase-activating protein 
3 Tmcc2 transmembrane and coiled-coil domains 2 
3 Tnks2 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 2 
3 Ube2h ubiquitin-conjugating enzyme E2H 
3 Zbtb48 zinc finger and BTB domain containing 48 
3 Zfp161 zinc finger protein 161  
3 Zfp408 zinc finger protein 408 
      
2 4930470P17Rik RIKEN cDNA 4930470P17 gene 
2 Atp7a ATPase, Cu++ transporting, alpha polypeptide 
2 BC006779 cDNA sequence BC006779 
2 Cabin1 calcineurin binding protein 1 
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2 Ccdc84 coiled-coil domain containing 84 
2 Ccrl1 chemokine (C-C motif) receptor-like 1 
2 Cd177 CD177 antigen 
2 BC035295 cysteine-serine-rich nuclear protein 2 
2 Ctdsp2 
CTD (carboxy-terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 2 
2 Diablo diablo homolog (Drosophila) 
2 Dnajb9 DnaJ (Hsp40) homolog, subfamily B, member 9 
2 H2afj H2A histone family, member J 
2 Hps5 Hermansky-Pudlak syndrome 5 homolog (human) 
2 Ikbip IKBKB interacting protein 
2 Itpkb inositol 1,4,5-trisphosphate 3-kinase B 
2 Klhl6 kelch-like 6 (Drosophila)  
2 Morc3 microrchidia 3 
2 Mycn 
v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 
2 Nfe2l1 nuclear factor, erythroid derived 2,-like 1 
2 Ostm1 osteopetrosis associated transmembrane protein 1  
2 Pafah1b3 
platelet-activating factor acetylhydrolase, isoform 1b, 
subunit 3 
2 Pdrg1 p53 and DNA damage regulated 1 
2 Phactr2 phosphatase and actin regulator 2 
2 Pik3r3 
phosphatidylinositol 3 kinase, regulatory subunit, 
polypeptide 3 (p55) 
2 Pogz pogo transposable element with ZNF domain 
2 Pon2 paraoxonase 2 
2 A430107D22Rik RAS protein activator like 3 
2 Rassf5 
Ras association (RalGDS/AF-6) domain family member 
5 
2 Rin3 Ras and Rab interactor 3 
2 Runx1 runt related transcription factor 1 
2 Sik3 SIK family kinase 3 
2 Sirt5 sirtuin 5  
2 Slc39a1 solute carrier family 39 (zinc transporter), member 1 
2 Slc9a9 
solute carrier family 9 (sodium/hydrogen exchanger), 
member 9 
2 Spnb2 spectrin beta 2 
2 Timm8a2 
translocase of inner mitochondrial membrane 8 
homolog a2 (yeast) 
2 Trp53inp2 
transformation related protein 53 inducible nuclear 
protein 2 
2 Tsc22d3 TSC22 domain family, member 3 
2 Unkl unkempt-like (Drosophila) 
2 Vamp5 vesicle-associated membrane protein 5 
2 Wdr26 WD repeat domain 26 
2 Ythdf2 YTH domain family 2 
2 Zfp28 zinc finger protein 2 	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 This work describes the adaptation of pool-based shRNA screening approaches 
to in vivo models of hematopoietic malignancies. In mammalian systems, both 
insertional mutagenesis screens and shRNA screens have been widely used for cancer 
gene discovery. While retroviral insertional mutagenesis screens have effectively 
identified genes that promote tumorigenesis in vivo, these screens are biased towards 
the identification of oncogenes and rarely identify tumor suppressors. It is also difficult to 
identify genes that negatively impact a disease process in these screens, because they 
rely on the positive selection of a given phenotype. Additionally, it is not possible to use 
these screening methodologies to systematically test the impact of a defined set of 
genetic lesions on tumor progression.   
 shRNA screens can be used to assess the effect of suppression of large sets of 
genes on tumor cell growth. Genes that either positively or negatively impact tumor cell 
proliferation can be identified, based on the enrichment or depletion of shRNAs targeting 
those genes. In insertional mutagenesis screens, positive selection only occurs for 
insertion events that are sufficient to promote transformation, strongly cooperate with 
other genetic alterations, or significantly accelerate transformation on sensitized 
backgrounds, whereas shRNA screens can identify genes whose suppression have 
more subtle phenotypic impacts.  
 However, in contrast to insertional mutagenesis screens, shRNA screens have 
primarily been performed in vitro in tumor cell lines. In instances where local 
environmental cues influence dependency on certain genes and pathways, the 
identification of these context-specific determinants of tumor progression may require 
that screens be performed within a physiologically relevant context. Thus, we were 
interested in developing approaches to perform shRNA screens in vivo. 
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 In previous work, it has been shown that genetic manipulations to hematopoietic 
tumors were sufficient to alter disease progression in vivo. For example, transplantation 
of chemoresponsive primary Eµ-myc lymphomas into secondary recipient mice after ex 
vivo transduction with a construct expressing Bcl2 produced chemoresistant tumors 
(Schmitt et al., 2000). Importantly, these tumors were transplanted into 
immunocompetent syngeneic recipient mice and transplanted tumors were 
pathologically indistinguishable from primary tumors, suggesting that the impact of 
individual genetic alterations on tumor progression can be studied in the context of a 
normal immune system and normal tumor microenvironment. Mimicking the impact of 
p53 loss in tumor development, shRNA-mediated suppression of p53 or Puma in 
transplanted Eµ-myc fetal stem cells was shown to accelerate lymphoma onset in 
recipient mice, indicating that shRNAs can be used in vivo to study loss of function 
phenotypes (Hemann et al., 2003; Hemann et al., 2004). In transplanted secondary Eµ-
myc lymphomas, suppression of p53, Topoisomerase1, or Topoisomerase2a by shRNAs 
were shown to impact chemotherapeutic outcome, further suggesting that shRNAs can 
effectively be used to examine the impact of specific genetic alterations in vivo (Burgess 
et al., 2008). 
 To identify novel genetic modulators of tumor cell growth in Eµ-myc lymphomas, 
we were interested in introducing a pooled shRNA library into primary lymphomas, and 
transplanting this transduced population into syngeneic recipient animals. Preliminary 
dilution experiments indicated that a minimum of 500 lymphoma cells were seeding 
disease following transplantation of primary lymphomas, suggesting that this model 
might accommodate the introduction of a relatively complex shRNA library. Therefore, 
we infected lymphoma cells with an shRNA library composed of 2200 shRNAs targeting 
1000 genes with known or putative roles in cancer. Lymphoma cells were either injected 
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into recipient animals or maintained in culture, allowing us to compare shRNAs that 
impacted lymphoma cell growth in the in vitro and in vivo settings. At the time of terminal 
disease, or after a comparable amount of time in culture, lymphoma cells were 
harvested and library pool composition was deconvoluted by high throughput 
sequencing. In this screen, we found that we could represent up to 900 unique shRNAs 
in the tumors of an individual animal, suggesting that a sufficient number of cells are 
seeding disease after transplantation to maintain library diversity, and therefore, screens 
using moderately-sized shRNA libraries can be performed in vivo. Additionally, when we 
compared the sets of shRNAs that enriched or depleted relative to the input cell 
population in vitro or in vivo, we found that scoring shRNAs were largely non-overlapping 
between these two settings. This suggests that context-specific genetic modulators of 
disease progression can be identified using in vivo screening approaches.  
 In validation studies, we showed that a number of regulators of cell migration 
influenced lymphoma progression specifically in the in vivo setting, including Rac2, CrkL, 
and the relatively poorly characterized actin binding protein Twinfillin. Suppression of 
these genes negatively impacted lymphoma cell dissemination, both to the lymph nodes 
and to sites of terminal metastatic disease, like the liver, lungs, and brain. Additionally, 
shRNA mediated suppression of Rac2 and Twinfillin in pure populations of lymphoma 
cells extended animal lifespan, at least in part by impairing these metastatic events. 
Furthermore, we found that shRNA-mediated suppression of Rac2 in lymphoma cells 
prolonged animal survival following treatment with the frontline chemotherapeutic 
vincristine, suggesting that sites of minimal residual disease following treatment may 
differ from sites of terminal disease, and the onset of morbidity after treatment requires 
Rac2-mediated cell migration to sites of terminal disease. Together, this data suggests 
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that modulators of cell migration may influence chemotherapeutic outcome in this 
lymphoma model. 
 We then extended this in vivo screening approach to a transplantable model of 
Bcr-Abl positive B-cell acute lymphoblastic leukemia. Here, when we introduced a library 
of 2200 shRNAs into transplanted tumors, we found that we could identify up to 1900 
unique shRNAs in an individual mouse, suggesting that very large numbers of 
transplanted cells are seeding disease in this model, and that this model might 
accommodate the introduction of complex shRNA libraries. Therefore, we decided to 
perform an in vivo screen for modulators of tumor growth using a genome-scale shRNA 
library, containing 5 pools of approximately 10,000 shRNAs each. Single pools of 10,000 
shRNAs were introduced into leukemia cells prior to transplantation, and transduced 
cells were either injected into syngeneic recipient mice or placed in culture. When 
leukemia cells were harvested from animals at the time of terminal disease, we found 
that, on average, we could identify between 7000 and 8000 unique shRNAs in the 
context of an individual mouse. Thus, this ALL model represents a system in which 
shRNA representation of a genome-scale library can be robustly maintained in the in 
vivo setting, allowing us to perform large-scale, unbiased screens. Whereas previous in 
vivo screens have been limited to assaying the impact of hundreds of shRNAs, here we 
are able to screen using tens of thousands of hairpins.  
 As in our previous work, we found that a large proportion of the sets of scoring 
shRNAs in the in vitro and in vivo settings were non-overlapping, suggesting that we are 
able to identify a subset of genes whose suppression may uniquely impact leukemia cell 
growth in vivo. Unsupervised hierarchical clustering of these samples patterns of 
enrichment or depletion of shRNAs were sufficient to distinguish cultured samples from 
in vivo samples. We focused our validation efforts on the set of hairpins that depleted 
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specifically in vivo, and to select candidates for validation we took a number of different 
approaches, including functionally categorizing the set of genes targeted by depleting 
hairpins, and filtering this dataset using both transcriptional data and human copy 
number alteration data.  
 Functional categorization of genes targeted by candidate hairpins showed that 
the products of these genes were enriched for a number of common protein domains, 
including C2H2-type zinc finger domains. A set of hairpins targeting C2H2 zinc finger 
proteins validated as single constructs, and we found that suppression of several poorly 
characterized C2H2 zinc finger proteins was selected against in leukemia cells 
specifically in the in vivo setting. In the course of our validation studies, we were able to 
identify numerous examples of genes whose suppression negatively impacts tumor cell 
growth in vivo, but is neutral or has the opposite effect in the in vitro setting, indicating 
that the in vivo tumor environment may alter the genetic dependencies of tumor cells. By 
performing shRNA screens in vivo, we can identify genes that are important specifically 
within this setting.  
 When the transcriptional profiles of leukemia cells harvested from mice were 
compared with those from leukemia cells proliferating in culture, we were again able to 
distinguish in vitro samples from in vivo samples using unsupervised hierarchical 
clustering, and found that a large number of genes were significantly differentially 
expressed in leukemia cells in vivo, relative to in vitro. This suggests that gene 
expression patterns, as well as the functional genetic dependencies of leukemia cells, 
may be altered by growth in the in vivo environment. However, when we compared the 
set of genes that were transcriptionally upregulated in vivo to genes targeted by shRNAs 
that depleted specifically in vivo, we found these sets to be primarily non-redundant. 
While this observation is consistent with data in yeast (Yeger-Lotem et al., 2009) it 
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suggests that, at least in this specific instance, transcriptional alterations are not well 
correlated with genes that are functionally important in disease progression. Other 
comparisons between matched microarray and screening datasets may show greater 
overlap between genes that are transcriptionally altered and genes targeted by hairpins 
that enrich or deplete in shRNA screens. 
 Runx and Lmo2 were contained in the limited set of genes that were both 
transcriptionally upregulated in leukemia cells in vivo and that were targeted by shRNAs 
that depleted in vivo in our screen, and in independent validation experiments, 
suppression of these genes was selected against in the in vivo setting. Given that the 
driving oncogenic lesion in this ALL model is the Bcr-Abl fusion protein, it was somewhat 
unexpected that these genes, which can drive transformation in other types of leukemia, 
would be functionally important in these tumors. Lmo2 translocations are found in a 
subset of T cell malignancies, and high levels of Lmo2 expression promote tumor 
development by blocking T cell differentiation and increasing thymocyte self renewal 
(Curtis and McCormack, 2010; McCormack et al., 2010). While Lmo2 expression has 
been measured in B-cell malignancies and was found to vary by subtype and genetic 
alteration (Malumbres et al., 2011; Natkunam et al., 2007), a functional role for this gene 
in B-lineage tumors has not been established. Runx translocations, found in 20-25% of 
B-cell ALLs, result in overexpression of the full-length protein (Blyth et al., 2005; Golub 
et al., 1995; Romana et al., 1995), and transcriptional upregulation of Runx has been 
observed in human B-ALL patients (Niini et al., 2002), suggesting that this gene may be 
oncogenic in B cell malignancies. Our data indicates that both Runx and Lmo2 promote 
tumor progression in Bcr-Abl driven tumors, and that activation of oncogenic pathways 
downstream of these genes may promote leukemia cell growth or survival specifically in 
the in vivo setting. 
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 When we mapped the location of the human orthologs of genes targeted by 
shRNAs that depleted specifically in the in vivo setting, we found that a number of these 
genes, including the plant homeodomain containing protein Phf6, fell within regions of 
amplification in human ALL patients. Plant homeodomain containing proteins recognize 
and bind to specific modifications on the lyseine tails of histones and are frequently part 
of multiprotein complexes that can activate or repress gene transcription (Musselman 
and Kutateladze, 2011; Sanchez and Zhou, 2011). Inactivating Phf6 mutations are 
frequently found in T-cell ALL (Van Vlierberghe et al., 2010), and less frequently, in AML 
(Van Vlierberghe et al., 2011) but have not been observed in B-cell malignancies (Van 
Vlierberghe et al., 2010). As a single constructs, multiple independent hairpins targeting 
Phf6 depleted specifically in BCR-Abl B-cell ALLs, and suppression of this gene was 
also selected against in Eµ-myc B cell lymphomas in vivo. This data suggests that, in 
contrast to T-cell ALLs, suppression of Phf6 in B cell malignancies impairs tumor 
progression. Whereas Phf6 suppression had no impact on tumor growth in T cell 
lymphomas, we found that Phf6 overexpression was selected against in these T cell 
tumors. This data is consistent with a model where Phf6 is necessary for the growth or 
survival of tumor cells in B cell malignancies, but expression of high levels of this gene 
impairs tumor progression in T cell malignancies. Additionally, this model is supported by 
data from human T cell malignancies, where loss of Phf6 in human patients, via 
mutation, is seen in a significant portion of T-cell ALLs.  
 We have shown have shown that moderate to large scale shRNA screens can be 
performed in vivo in mouse models of hematopoietic malignancies. By using 
transplantable models of established tumors that can be manipulated ex vivo, we can 
introduce libraries of shRNAs into tumor cells, transplant transduced cells into recipient 
animals, and compare shRNA representation in the resulting tumors to representation in 
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an input cell population in order to identify shRNAs that impact leukemia or lymphoma 
cell growth in vivo. Other groups have used similar strategies to identify genes that 
accelerate tumor development in Eµ-myc tumors (Bric et al., 2009) and hepatocelluar 
carcinoma (Zender et al., 2008). In these screens, low complexity pools of approximately 
50 shRNAs each were introduced into cells prior to transplantation. More recently, a 
screen using a pool of nearly 1000 shRNAs was performed in an inducible, 
transplantable model of AML, and in this work control shRNAs targeting an essential 
gene consistently depleted in transplanted tumors (Zuber et al., 2011). To our 
knowledge, our screening work in acute lymphoblastic leukemia represents the first 
unbiased, genome-scale screen that has been performed in vivo. 
 Importantly, screens in vivo yield different sets of scoring shRNAs when 
compared to matched in vitro screens. Thus, these screens are not simply recapitulating 
the results of in vitro screens, but may help identify novel modulators of tumor 
progression. A subset of the scoring shRNAs are shared between in vitro and in vivo 
screens, and these are expected to target essential genes and key downstream 
modulators of oncogenic signals. In vivo cues may provide a unique signaling 
environment and thus alter the genes and pathways that are required for tumor cell 
proliferation and survival. Therefore, in vivo screens may help identify the unique genetic 
dependencies of tumor cells within the normal tumor microenvironment, and ultimately, 
could aid in the development of therapeutic strategies that exploit these dependencies. 
While it is currently difficult to assign a function to many of the shRNAs that specifically 
impact tumor cell growth in vivo, and derive a coherent biology from this set of scoring 
hairpins, continued study of these genes in the in vivo context may help clarify their role 
in disease progression. 
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 A number of challenges accompany in vivo screens. One challenge that is 
shared with in vitro screening approaches is the selection of candidate hits for validation. 
Screens with genome-scale libraries produce large numbers of candidate hits, especially 
in screens that have the resolution to identify hairpins with intermediate phenotypes. The 
cost of systematically validating all of these candidate hits as individual constructs is 
prohibitive, particularly when validation assay are in vivo, but selectively validating a very 
limited number of hairpins without a clear rationale disregards any value or insight that 
can be obtained from the dataset as a whole. One approach to selecting candidate hits 
for validation is identifying pathways or functional categories that are overrepresented in 
genes targeted by scoring shRNAs, although programs designed for this purpose 
necessarily exclude uncharacterized or poorly characterized genes, and well-studied 
genes and pathways are often over-represented. Comparisons with human tumor gene 
expression data, mutational data, and copy number alteration data provide another 
means of filtering candidate hits for validation. 
 Another method of rapidly validating sets of candidate shRNAs is the 
construction of high-coverage validation libraries. In our ALL screen, we identified a set 
of approximately 130 genes that were both transcriptionally upregulated in vivo and 
targeted by depleting shRNAs. Rather than selecting a subset of these for validation, we 
designed six independent shRNAs that targeted each gene, bulk synthesized and cloned 
this library, and directly used this bulk-cloned product to repeat our initial screen. Without 
sequence verifying individual constructs and pooling sequence-verified clones, we 
estimate that about 25% of this bulk-cloned library contains oligonucleotides that were 
mis-synthesized, and therefore non-functional. Because each hairpin is represented by 
many oligonucleotides, for any given hairpin, the library contains both correct and 
incorrect oligonucleotides. Mis-synthesized hairpins should behave as neutral constructs 
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in the validation screens, and if functional and non-functional hairpins cannot be 
resolved in the quantification of pool representation, they may dampen the apparent 
enrichment or depletion of functional hairpins. However, using this approach, the 
considerable savings in cost and time may make the construction of small custom 
libraries an effective validation strategy. Genes with multiple independent hairpins that 
score in secondary screens can then be selected for validation as individual constructs. 
Secondary screens may be especially useful when libraries that contain only 2-3 hairpins 
per gene were used for primary screens, or in cases where the hairpin coverage of each 
gene was highly variable. 
 Another challenge in performing in vivo screens is the identification of models 
that are appropriate for screening purposes. Since the delivery of pools of shRNAs to 
tissues is challenging, transplantable tumors are the simplest models for in vivo screens. 
Thus far, our work has been limited to models of hematopoietic malignancies, although 
in vivo screens have also been performed in a transplantable liver model, and it should 
be possible to use these approaches in transplantable models of other solid tumors. One 
key consideration in the selection of tumor models for screens is the number of cells that 
seed disease following tumor cell transplantation. If only small numbers of cells are 
seeding disease following transplantation, the representation of shRNA libraries will be 
severely limited. The number of cells seeding disease can be estimated by infecting cells 
with a hairpin that has known and identifiable phenotype prior to transplantation, and 
seeing if that hairpin can be reproducibly identified in transplanted tumors. For example, 
if a hairpin that is infected to 0.5% is consistently found in transplanted tumors, this 
indicates that at least 200 cells are seeding disease in tumors. Alternatively, libraries of 
shRNAs can be introduced into cells prior to transplantation, and the number of unique 
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hairpins found in individual tumors can be quantified as a proxy for the number of cells 
seeding disease.  
 An approximation of the number of hairpins seeding disease is important when 
selecting the appropriate shRNA pool size to use for screens. Generally, it is preferable 
that the number of cells seeding disease exceeds the number of hairpins in a library. 
Otherwise, some proportion of shRNAs will stochastically drop out of each tumor, 
because cells containing those hairpins don’t contribute to the population of cells that 
seed disease. If the same shRNAs stochastically drop out of all tumors in an 
experimental group, these hairpins will appear to deplete, but may actually have no 
biological impact. In instances where smaller numbers of cells are seeding disease in 
transplanted tumors, it is still possible to perform shRNA screens, but with less complex 
shRNA pools. In these cases, in vivo screens may be more appropriate for testing 
targeted shRNA libraries that contain sets of genes that are involved in a particular 
process of interest. 
 In both of the in vivo screens we have performed, we have consistently observed 
that the variability between samples was higher for in vivo samples than cultured 
samples. We think the tumor microenvironment may cause fluctuations in the 
representation of tumor cells containing neutral hairpins, and differential numbers of cell 
containing particular hairpins seeding disease may also contribute to this variation 
between samples. Our group has shown that the coefficient of variation between 
samples is smaller in validating hairpins, relative to the cumulative behavior of all 
hairpins in vivo, suggesting that we may be able to accurately identify hairpins that are 
likely to validate as individual constructs by using cutoffs that select shRNAs exhibiting 
low variability between samples (Pritchard et al., 2011).  
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 Whereas in vivo validation of hits from insertional mutagenesis screens or 
transposon screens requires generating transgenic animals and directly testing the 
impact of a specific alteration on tumor development, hits from in vivo shRNA screens 
can be rapidly functionally validated. Tumor cells can be partially transduced with single 
shRNA constructs coexpressing GFP, and assaying for a change in the proportion of 
cells that contain GFP provides a sensitive means to detect alterations in growth and 
survival conferred by the presence of shRNAs. Here, the rate of validation of candidate 
hits can be used as a measure of the quality of the screening dataset, and genes whose 
loss has a functional impact on tumor cell growth can easily be identified. 
 Given the success of performing pool-based shRNA screens in vivo, we think 
that these approaches may be used to examine other aspects of tumor cell biology, such 
as resistance to chemotherapeutics. Clinical resistance to the targeted 
chemotherapeutic dasatanib in BCR-Abl B-cell acute lymphoblastic leukemia is a serious 
challenge, and a portion of this resistance occurs without mutations in the Abl kinase 
domain that prevent drug binding. Therefore, an in vivo screen for shRNAs that sensitize 
leukemia cells to dasatinib treatment may elucidate pathways that are important for drug 
resistance in vivo, and may also provide potential strategies to increase the efficacy of 
drug treatment. Similarily, screens with conventional chemotherapeutics may also yield 
insights to mechanisms of resistances in the in vivo microenvironment.  
 In vivo shRNA-based screens could also be used to identify modulators of 
metastasis. In hematopoietic cancers, metastasis to the central nervous system 
represents a clinical challenge, and mechanisms of leukemia or lymphoma cell migration 
to the brain are poorly understood. Thus, an in vivo screen comparing shRNA 
representation in the blood to shRNA representation in leukemia cells in the brain might 
be used to identify modulators of CNS metastasis. As in vivo screening approaches are 
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extended to other models of solid tumors, genes that are involved in metastasis in these 
diseases could be identified in a similar manner.  
 In vivo screening approaches can be a useful tool for unbiased cancer gene 
discovery, and as described here, may aid in the future identification of genes that are 
important in many stages of tumor progression. 
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